Non-human animal formula supplement, feed, extract and use thereof
By using polyphenol extracts derived from sugarcane in animal feed, the agricultural challenges brought about by antibiotic resistance are solved, animal health and growth performance is improved, and effective solutions for antibiotic alternatives are provided, which is economical and environmentally friendly. food production.
Patent Information
- Application Number
- CN202411084668.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-05-11
- Filing Date
- 2019-05-08
- Publication Date
- 2024-11-22
AI Technical Summary
The problem of antibiotic resistance leads to a reduced efficacy of antibiotic use, agriculture faces economic burdens and common problems of animal diseases, and the need to develop antibiotic alternatives to improve the quality of food production and reduce the spread of diseases.
Polyphenol extracts derived from sugar cane are used as animal feed additives to improve or maintain the health of animals, improve growth performance, reduce body fat content, improve nutrient digestibility and gastrointestinal health, prevent anemia and muscle conditions, and stimulate appetite.
Effectively replaces the function of antibiotics, improves the growth performance and health of animals, reduces feed conversion, improves meat quality and nutrient digestion, reduces disease risks, and provides economical and environmentally friendly alternatives.
Smart Images

Figure CN118985769A_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application with application number 201980045643.9, whose application date is May 8, 2019 and whose invention name is “Sugarcane Extract for Animal Feed”. Technical Field
[0002] The present disclosure relates to animal supplements and feeds comprising extracts derived from sugar cane, and in particular to animal supplements and feeds comprising polyphenol extracts derived from sugar cane. The present disclosure also relates to animal supplements, animal feeds, methods and uses for improving or maintaining animal health to facilitate improved food production and food quality.
[0003] Throughout this disclosure, various publications are cited by first author and year of publication. Full citations for these publications are listed in the "References" section in the order in which they appear in this application. Background Art
[0004] Antibiotic use has become a staple of animal production around the world. Antibiotics are used as additives or supplements in animal feed not only to control infection but also to promote growth. Antibiotics are thought to help animals digest food more efficiently, improving the quality and yield of food, which can provide economic benefits to farmers.
[0005] Antibiotic resistance (AMR) is a natural process whereby microorganisms evolve to resist the effects of drugs, rendering them ineffective. This causes the effectiveness of antibiotics to decrease over time, and in extreme cases, the antibiotics are ultimately useless. AMR is increasingly a problem because the rate at which new antibiotics are being discovered has slowed dramatically, so the number of new drugs is very limited. At the same time, the use of antibiotics has increased, in part due to the adoption of intensive farming practices. AMR threatens the effective prevention and treatment of an ever-expanding range of infections caused by bacteria, parasites, viruses and fungi, and is becoming a growing threat to public health worldwide. The widespread use and overuse of antibiotics has led to the emergence of life-threatening “superbugs” that are resistant to several classes of antibiotics.
[0006] In the new “post-antibiotic era”, major government agencies (EU, US FDA, Australian Department of Agriculture and Health) are responding to AMR by implementing directives and regulations to control the use of antibiotics in food. Major companies in the food industry, such as McDonalds and Walmart, are launching their own initiatives to reduce the use of antibiotics.
[0007] However, a consequence of phasing out antibiotic use is that without growth-promoting antibiotics, food production levels will fall, placing a greater economic burden on agriculture. The reduction in antibiotics has also led to some animal diseases becoming more widespread and prevalent.
[0008] Therefore, it is important to increase and develop the equipment of pharmaceutical agents that have the potential to serve as alternatives to antibiotics.In the "post-antibiotic era", there is a need for medicated animal feeds that can be used to alleviate problems associated with AMR and the reduction of antibiotics.
[0009] Any discussion of documents, acts, materials, devices, articles or the like included in this disclosure should not be taken as an admission that any or all of these matters form part of the prior art base or are common general knowledge in the field relevant to the present disclosure as it existed before the priority date of this application. Summary of the invention
[0010] Sugar cane waste and sugar cane extracts can provide various benefits to humans and animals: certain phytochemical-containing sugar cane extracts can be used as nutritional supplements, while other phytochemical-containing sugar cane extracts have the ability to lower the glycemic index (GI) of foods and beverages. The present disclosure is based on the discovery that polyphenol extracts derived from sugar cane have surprising and favorable properties for improving or maintaining the health of animals.
[0011] In one aspect of the present disclosure, a non-human animal formula supplement is provided that includes an extract derived from sugar cane that includes about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0012] In another aspect of the present disclosure, a non-human animal feed is provided that includes a supplement as described herein.
[0013] In another aspect of the present disclosure, a method for improving or maintaining gastrointestinal health in a non-human animal subject is provided, the method comprising the step of administering an effective amount of a supplement described herein or a feed described herein.
[0014] In another aspect of the present disclosure, a method for improving growth performance of a non-human animal subject is provided, the method comprising the step of administering an effective amount of a supplement described herein or a feed described herein.
[0015] In another aspect of the present disclosure, a method for reducing body fat content in a non-human animal subject is provided, the method comprising the step of administering an effective amount of a supplement described herein or a feed described herein.
[0016] In another aspect of the present disclosure, a method for improving nutrient digestibility in a non-human animal subject is provided, the method comprising the step of administering to the subject an effective amount of a supplement described herein or a feed described herein.
[0017] In another aspect of the present disclosure, a method for reducing feed conversion ratio (FCR) in a non-human animal subject is provided, the method comprising administering to the subject an effective amount of a supplement described herein or a feed described herein.
[0018] In another aspect of the present disclosure, a method for improving meat quality in a non-human animal subject is provided, the method comprising administering to the subject an effective amount of a supplement described herein or a feed described herein.
[0019] In another aspect of the present disclosure, a method for preventing and / or treating anemia in a non-human animal subject is provided, wherein the method comprises the step of administering an effective amount of a supplement described herein or a feed described herein.
[0020] In another aspect of the present disclosure, a method for improving or maintaining muscle condition in a non-human animal subject is provided, wherein the method comprises the step of administering an effective amount of a supplement as described herein or a feed as described herein.
[0021] In another aspect of the present disclosure, a method for stimulating or maintaining appetite in a non-human animal subject is provided, wherein the method comprises the step of administering an effective amount of a supplement as described herein or a feed as described herein.
[0022] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for improving or maintaining gastrointestinal health in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0023] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for improving growth performance in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0024] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for reducing body fat content in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0025] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for improving nutrient digestibility in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0026] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for reducing feed conversion ratio (FCR) of a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0027] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for improving meat quality in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0028] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a medicament for preventing and / or treating anemia in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0029] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for improving or maintaining muscle condition in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0030] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for stimulating or maintaining appetite in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0031] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0032] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for use in improving or maintaining gastrointestinal health in a non-human animal subject is provided.
[0033] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for improving growth performance in a non-human animal subject is provided.
[0034] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for use in reducing body fat content in a non-human animal subject is provided.
[0035] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for improving nutrient digestibility in a non-human animal subject is provided.
[0036] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for reducing feed conversion ratio (FCR) in a non-human animal subject is provided.
[0037] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for improving meat quality in a non-human animal subject is provided.
[0038] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for use in preventing and / or treating anemia in a non-human animal subject is provided.
[0039] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for use in preventing and / or treating iron deficiency anemia in a non-human animal subject is provided.
[0040] In another aspect of the present disclosure, a non-human animal formulation supplement as described herein for improving or maintaining muscle condition in a non-human animal subject is provided.
[0041] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for stimulating or maintaining appetite in a non-human animal subject is provided.
[0042] In another aspect of the present disclosure, a non-human animal feed as described herein for use in improving or maintaining gastrointestinal health in a non-human animal subject is provided.
[0043] In another aspect of the present disclosure, a non-human animal feed as described herein for improving growth performance of a non-human animal subject is provided.
[0044] In another aspect of the present disclosure, a non-human animal feed as described herein for reducing body fat content in a non-human animal subject is provided.
[0045] In another aspect of the present disclosure, a non-human animal feed as described herein for improving nutrient digestibility in a non-human animal subject is provided.
[0046] In another aspect of the present disclosure, a non-human animal feed as described herein for reducing the feed conversion ratio (FCR) of a non-human animal subject is provided.
[0047] In another aspect of the present disclosure, a non-human animal feed as described herein for improving meat quality in a non-human animal subject is provided.
[0048] In another aspect of the present disclosure, a non-human animal feed as described herein for use in preventing and / or treating anemia in a non-human animal subject is provided.
[0049] In another aspect of the present disclosure, a non-human animal feed as described herein for use in preventing and / or treating iron deficiency anemia in a non-human animal subject is provided.
[0050] In another aspect of the present disclosure, a non-human animal feed as described herein for improving or maintaining muscle condition in a non-human animal subject is provided.
[0051] In another aspect of the present disclosure, a non-human animal feed as described herein for stimulating or maintaining appetite in a non-human animal subject is provided.
[0052] In another aspect of the present disclosure, a non-human animal formula supplement is provided that includes an extract derived from sugar cane, the extract including about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols, wherein the extract includes iron bound to the polyphenols. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] Although it will be appreciated that various embodiments of the present disclosure may be utilized, in the following, several examples of the present disclosure are described with reference to the following figures:
[0054] Figure 1 A process flow for preparing an extract derived from molasses is shown.
[0055] Figure 2A process flow for preparing an extract derived from dregs is shown.
[0056] Figure 3 A process flow for preparing extracts derived from dregs and molasses is shown.
[0057] Figure 4 The results of LCMS analysis show Figure 1 Base peak chromatograms (FTMS negative) of three extracts from molasses produced by the process of FIG. 1 . A) Resin bound sample, B) Unbound sample, and C) 74°Brix sample.
[0058] Figure 5 An LC-MS spectrum of a representative extract derived from sugar cane molasses prepared according to Example 3 is shown.
[0059] Figure 6 Shown are LC-MS spectra of a bagasse starting material (A) and an extract of bagasse according to the present invention (B).
[0060] Figure 7 Shown are representative binding curves of sugar cane-derived extracts of the present disclosure to nuclear factor kappa B (NF-κB).
[0061] Figure 8 Shown are representative response curves of sugar cane-derived extracts of the present disclosure to erythroid-derived nuclear factor 2-related factor (Nrf2).
[0062] Fig. 9 Shown are representative binding curves of sugar cane-derived extracts of the present disclosure to tumor necrosis factor (TNF-α).
[0063] Fig.10 Representative inhibition curves of sugar cane-derived extracts of the present disclosure with prostaglandin E2 (PGE2) are shown.
[0064] Fig.11A and Fig. 11B Representative inhibition curves of sugar cane-derived extracts of the present disclosure against cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) are shown.
[0065] Fig.12 The average growth chart of Pangus studied in Example 13 by weight (g) is shown.
[0066] Fig.13 A graph showing the average growth of the Pangasius studied in Example 13 by length (cm) is shown.
[0067] Fig.14The average weight gain graph (g) of Pangasius studied in Example 13 is shown.
[0068] Fig.15 The average growth graph (cm) of Pangasius studied in Example 13 is shown.
[0069] Fig.16 Photos of Pangasius studied in Example 13 are shown by treatment groups: A. T0 - control group; B. T1 - treatment group (0.2% extract); C. T2 - treatment group (0.4% extract); D. T3 - treatment group (0.6% extract).
[0070] Fig.17 Shown is a size comparison of Pangasius studied in Example 13 between T0, T1, T2 and T3 treatment groups.
[0071] Fig.18 The average growth graph by weight (g) of the tilapia studied in Example 13 is shown.
[0072] Fig.19 A graph showing the average growth of tilapia by length (cm) studied in Example 13 is shown.
[0073] Fig. 20 The average weight gain graph (g) of tilapia studied in Example 13 is shown.
[0074] Fig.21 A graph showing the average growth of tilapia by length (cm) studied in Example 13 is shown.
[0075] Fig. 22 Photographs of tilapia studied in Example 13 are shown by treatment groups: A. T0 - control group; B. T1 - treatment group (0.2% extract); C. T2 - treatment group (0.4% extract); D. T3 - treatment group (0.6% extract).
[0076] Fig.23 Shown is a size comparison of tilapia studied in Example 13 between the T0, T1, T2, and T3 treatment groups.
[0077] Fig.24 The average growth graph of the prawns studied in Example 13 by weight (g) is shown.
[0078] Fig.25 A graph showing the average growth by length (cm) of the shrimp studied in Example 13 is shown.
[0079] Fig.26Shown is a graph of average weight gain of the shrimp studied in Example 13 (g). The graph of average weight gain shows a bar graph depicting the average weight gain of the T0, T1, T2 and T3 treatment groups: the left bar graph is the average weight gain (sample 9) in the treatment group, and the right bar graph is the average weight gain (sample 10) in the treatment group.
[0080] Fig. 27 The average growth graph (cm) of the shrimp studied in Example 13 is shown.
[0081] Fig.28 Photographs of the shrimp studied in Example 13 are shown by treatment groups: A. T0 - control group; B. T1 - treatment group (0.2% extract); C. T2 - treatment group (0.4% extract); D. T3 - treatment group (0.6% extract).
[0082] Fig.29 Shown is a size comparison of the shrimp studied in Example 13 between the T0, T1, T2 and T3 treatment groups.
[0083] Fig. 30A and 30B Graph showing the average daily increments for the chicken study of Example 14: Fig. 30A .Day 10-17 (starting period), Fig. 30B .Day 17-24 (growth period).
[0084] FIG. 31A to FIG. 31C Graph showing weight gain for the chicken study of Example 14: Fig.31A .The average daily increment during the 24th to 38th day, Fig.31B .Weight gain on day 38; and Fig.31C .Graph of average daily feed intake during days 24-38.
[0085] Fig.32 The structures of the treatment groups in the cat study of Example 15 are shown. Compound X refers to the sugar cane extract of Example 3.
[0086] Fig.33 The effects of the extract of the present disclosure on blood health parameters observed in the cat study of Example 9 are shown. Abbreviations: MCH (mean corpuscular hemoglobin); MCHC (mean corpuscular hemoglobin concentration); HCT (hematocrit). The left bars of the bar graph relate to the data for the control, while the right bars relate to the data for the sugar cane extract of Example 3.
[0087] Fig.34The effects of the extract of the present disclosure (Extract of Example 3) on other blood health parameters observed in the cat study of Example 15 are shown. Abbreviation: Seg Neut (segmented nuclear neutrophils). The left bars of the bar graph relate to the data of the control, while the right bars relate to the data of the sugar cane extract of Example 3 (referred to as "Compound" in the figure).
[0088] Fig.35 The effects of the extract of the present disclosure (Extract of Example 3) on urinary health parameters observed in the cat study of Example 15 are shown: the y-axis values are the reference (normal) ranges for each component. Values are reported as mean and SED. The left bars of the bar graph relate to the data for the control, while the right bars relate to the data for the sugar cane extract of Example 3 (referred to as "Compound" in the figure).
[0089] Fig.36 The effects of the extract of the present disclosure (Extract of Example 3) on the digestibility of macronutrients observed in the cat study of Example 15 are shown. Values are reported as mean and SED. The left bars of the bar graph relate to the data for the control, while the right bars relate to the data for the sugar cane extract of Example 3 (referred to as "Compound" in the figure).
[0090] Fig.37A and Fig.37B The effects of the extract of the present disclosure (Extract of Example 3) on A. body composition and B. body weight observed in the cat study of Example 15 over 30 weeks are shown, wherein Fig.37A Lean body mass (kg) and Fig.37B Body weight (kg) is shown. Body composition was determined using deuterated water (D2O) injection or dual energy X-ray absorptiometry (DEXA). Values are reported as mean and SED. The left bars of the bar graphs relate to the data for the control, while the right bars relate to the data for the sugar cane extract of Example 3 (referred to as "Compound" in the figure).
[0091] Fig.38 A diagram showing the crossover trial for the cat study of Example 9. CC represents a control diet administered for 31 weeks; CX represents a control diet for 18 weeks followed by a switch to a sugar cane extract diet for the remainder of the trial; XC represents a sugar cane extract diet for 18 weeks followed by a switch to a control diet for the remainder of the trial; XX represents a sugar cane extract diet administered for 31 weeks.
[0092] Fig.39A and Fig.39B The effects of the extract of the present disclosure (the extract of Example 3) on body fat composition observed in the cat study of Example 15 are shown, wherein Fig.39A The % fat is shown as well Fig.39BFat mass (kg) is shown. Body composition was determined using deuterated water (D2O) injection or dual energy X-ray absorptiometry (DEXA). Values are reported as mean and SED. The left bars of the bar graphs relate to the data for the control, while the right bars relate to the data for the sugar cane extract of Example 3 (referred to as "Compound" in the figure).
[0093] Fig.40 A line graph showing energy intake over 18 weeks for the cat study of Example 15. The upper line labeled "C" shows the trend for the control diet; the lower line labeled "X" shows the trend for the sugar cane extract diet based on the extract of Example 3.
[0094] Fig.41 The % fat body content as measured by DEXA is shown for the cat study of Example 15. The line graph shows the trend of % fat body content over 18 weeks. The upper line "C" shows the trend for the control diet; the lower line "X" shows the trend for the sugar cane extract diet based on the extract of Example 3.
[0095] Fig.42A and Fig.42B The horse A of Example 11 is shown before ( Fig.42A ) and after ( Fig.42B )’s photos.
[0096] Fig.43A and Fig.43B Before and after photos of Horse B of Example 11 are shown.
[0097] Fig.44A and Fig.44B Before and after photos of Horse C of Example 11 are shown.
[0098] Fig.45A and Fig.45B Before and after photos of Horse D of Example 11 are shown.
[0099] Fig.46A and Fig.46B Before and after photos of Horse E of Example 11 are shown.
[0100] Fig.47 A graph showing an overview of the temperature conditions and basic diet used in Example 18 is shown.
[0101] Fig.48 A graph of body weight (g) of broiler chickens of Example 18 versus increasing sugar cane extract diet (based on the extract of Example 3) is shown, with the dashed line showing a positive trend.
[0102] Fig.49 A graph of feed conversion ratio (FCR) with increasing sugarcane extract diet (based on the extract of Example 3) is shown, with the dashed line showing a negative trend.
[0103] Fig.50 The Walden-Brown shear stress (WBSF, kg / cm 2 ) with a sugarcane extract diet based on the extract of Example 3 at levels of 0, 2, 4, 6 and 10 g / kg.
[0104] Figure 51(a) shows a graph of thiobarbituric acid reactive substances (TBARS) with a sugarcane extract diet based on the extract of Example 3 at 0, 2, 4, 6 and 10 g / kg in broiler chickens in the thermoneutral (TN) group over 24 and 72 hour periods.
[0105] Figure 51(b) shows a graph of thiobarbituric acid reactive substances (TBARS) with a sugarcane extract diet based on the extract of Example 3 at 0, 2, 4, 6 and 10 g / kg in broiler chickens in the heat stress (HS) group over the 24 hour and 72 hour time periods. DETAILED DESCRIPTION
[0106] definition
[0107] Unless otherwise clearly defined, all technical terms and scientific terms used herein should have the same meaning as those generally understood by ordinary technicians in the field (e.g., chemistry, biochemistry, formulation science, food and nutritional science, animal science and animal husbandry, cell culture and molecular biology). In addition, unless the context requires otherwise, singular terms should include plural terms, and plural terms should include singular terms. Therefore, as used in this specification, the singular forms of "one", "a kind" and "the" include plural objects, unless the context clearly indicates otherwise. Therefore, the term "an animal subject" refers to "one or more animal subjects", unless the context clearly indicates otherwise.
[0108] As used herein, the term "about" refers to a range of + / - 5% of a specified value.
[0109] "Administering" as used herein should be interpreted broadly to include administering an extract or animal supplement or animal feed described herein to an animal subject. The term encompasses normal consumption of food and water by an animal subject as well as oral administration (including buccal or sublingual). The term "administering" as used herein also encompasses administration by nasal administration.
[0110] As used herein, the term "animal feed" refers to any compound, preparation or mixture suitable or intended for ingestion by an animal.
[0111] As used herein, "animal supplement" refers to substances added to feed for purposes including, but not limited to, enhancing the digestibility of the feed, improving the nutritional value of the feed, improving or maintaining the health of the recipient (e.g., improving immunity), or improving or maintaining gastrointestinal health.
[0112] As used herein, the term "animal subject" refers to any animal other than a human. Thus, the present disclosure relates to non-human animals. The non-human animal may be a mammal. Examples of non-human animals include aquatic animals, insects, amphibians, reptiles, gastropods, birds, monogastric animals, ruminants, and pseudo-ruminants.
[0113] The term "aquatic animals" as used herein includes fish, including but not limited to finfish and shellfish. Finfish include but are not limited to pangasius and tilapia. Other examples of finfish include barramundi, bass, bream, carp, catfish, cod, crappie, drum, eel, goby, goldfish, grouper, halibut, java, labeo, lai, loach, mackerel, milkfish, mojarra, mudfish, mullet, paco, pearlspot, pejerrey, perch, pike, pompano, roach, salmon, sampa, sauger, sea bass, and mullet. The term "shellfish" refers to a group of fish that includes, but is not limited to, molluscs (e.g., clams, mussels, oysters, scallops, and shellfish). Shellfish include, but are not limited to, crustaceans (e.g., crabs, crayfish, lobsters, prawns, and shrimps) and mollusks (e.g., clams, mussels, oysters, scallops, and shellfish).
[0114] Insects include, for example, cicadas, grasshoppers, beetles, bees, wasps, butterflies, moths, ants, flies, crickets, aphids, bedbugs, and dragonflies.
[0115] Amphibians include, for example, frogs, toads, and salamanders.
[0116] Reptiles include, for example, snakes, lizards, iguanas, turtles, and crocodiles.
[0117] Gastropods include, for example, snails and slugs, including sea snails and sea slugs, as well as freshwater snails, freshwater limpets, terrestrial snails, and terrestrial slugs.
[0118] Birds include poultry such as chickens, ducks, geese, turkeys, quail, guinea fowl, pigeons (including chicks) and birds of prey (including eagles, hawks, kites, falcons, vultures, harriers, ospreys and owls). Chickens include, for example, broilers (broilers), chickens, roosters and laying hens (layers).
[0119] Monogastric animals include, but are not limited to, pigs or swine (eg, piglets, growing pigs, and sows), cats and dogs, rodents (rats, mice).
[0120] Ruminants include animals such as cattle, sheep, goats, deer, yaks, camels, llamas, and kangaroos. Cattle include, but are not limited to, beef cattle, dairy cows, cows, and calves.
[0121] Pseudoruminants include, for example, horses, camels, rabbits, and guinea pigs.
[0122] The term "animal subject" encompasses companion animals, food animals as defined herein, and aquarium and zoo animals.
[0123] As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combination of the specified ingredients.
[0124] As used herein, the terms "improvement", "treatment", and the like refer to controlling, curing, or alleviating a disease, disorder, or condition, or reducing the rate of development of a disease, disorder, or condition, or resisting or inhibiting symptoms or side effects, reducing the severity of the development of symptoms or side effects, and / or reducing the number or type of symptoms or side effects suffered by an animal subject, compared to a veterinary composition, animal supplement, or animal feed comprising an extract derived from sugar cane without the administration of the present disclosure. The term "alleviation" encompasses relieving adverse symptoms, inducing a state of comfort or health, or removing or reducing the biochemical, physiological, or clinical indicators of a condition, disease, or disorder. As used herein, the terms "prevention", and the like refer to avoiding, delaying, reducing, or slowing the onset of a specified disease, disorder, or condition, or avoiding at least one symptom or side effect of a condition, disease, or disorder. As will be understood by those skilled in the art, the term "prevention" includes, for example, complete prevention of anemia, but this does not necessarily mean that anemia is completely prevented. Likewise, it will be appreciated that the terms "improvement" or "treatment" include, for example, the curing of anemia, but this does not necessarily mean that anemia is completely cured. When used in the phrase "maintaining gastrointestinal health," the terms "maintain" and the like refer to inducing or causing gastrointestinal health to persist, thereby maintaining gastrointestinal health.
[0125] With respect to "improvement," "maintenance," "prevention," and "treatment," the term "effective amount," as used herein, refers to an amount of (sugar cane extract or composition, non-human animal formula supplement comprising the extract, or non-human animal feed) sufficient to elicit a biological or medical response in a tissue, system, animal, or human when administered to an animal, which is what practitioners in the animal husbandry field (e.g., farmers, researchers, or veterinarians) are seeking. Undesirable effects (e.g., side effects) sometimes occur along with the desired effects; therefore, practitioners balance potential benefits against potential risks in determining what an appropriate "effective amount" is. The exact "effective amount" required varies from subject to subject, depending on the species, age, and general condition of the subject, the mode of administration, the severity of the disease, and the like. Therefore, it is not possible to specify an exact "effective amount." However, in any individual case, an appropriate "effective amount" can be determined by a person of ordinary skill in the art using routine experimentation. The terms "improvement," "maintenance," "prevention," and "treatment" encompass use in palliative care.
[0126] The term feed conversion ratio (FCR) as used herein refers to a measure of the efficiency with which an animal converts the mass of feed into an increase in the expected yield. For edible animals raised for meat, such as fish, poultry, cattle and pigs, the yield is the mass that the animal increases. Specifically, unless otherwise expressly stated in the present disclosure, FCR is calculated as feed intake divided by weight gain over a specific period. An improvement in FCR means a decrease in the FCR value. A 2% improvement in FCR means a 2% decrease in FCR.
[0127] The term "fiber" as used herein refers to the indigestible part of a food derived from a plant. Fiber can be soluble or insoluble fiber. Non-limiting examples of fiber include sugar cane fiber, oat bran, flour (including, for example, soy, rice, wheat, bran, rye, corn, sorghum, potato), modified starch, gelatin, non-starch polysaccharides such as arabinoxylan, cellulose, and many other plant components such as resistant starch, resistant dextrin, inulin, lignin, chitin, pectin, beta-glucan, and oligosaccharides.
[0128] As used herein, the term "food animal" refers to an animal that is raised to produce food for consumption by another animal (e.g., a human). It should be understood that the term "food animal" encompasses food animals that are aquatic animals; food animals that are birds; food animals that are monogastric animals; food animals that are rodents; and food animals that are pseudo-ruminants. It should be understood that the term "food animal" includes, for example, finfish, shellfish, poultry (such as chickens, geese, and turkeys), pigs, cattle, sheep, goats, and horses.
[0129] As used herein, the term "growth performance" refers to the response of an animal subject to an extract derived from sugar cane, an animal supplement, or an animal feed of the present disclosure. Growth performance can be assessed by methods known in the art and can be characterized by any one or more of the following: feed conversion rate, feed intake, weight gain, increase in size (e.g., increase in length). Growth performance can also be characterized by food production including meat yield or milk yield.
[0130] It should be understood that the size of an animal can be measured according to any physical dimension, such as body length, width, thickness and girth, and head length, width, thickness and girth. It should be understood that such measurements have been standardized to facilitate comparisons between, for example, different animals of the same species. As an illustration, when measuring finfish, "standard length" as used herein refers to the measurement from the snout of the finfish to the last vertebra. If the last vertebra is difficult to determine, other measurements may be used. In this regard, "fork length" refers to the measurement from the snout to the intersection of the caudal fin at the tail.
[0131] The terms "CE" or "catechin equivalents" and the term "GAE" or "gallic acid equivalents" as used herein are measures of total polyphenol content. The terms "CE" or "catechin equivalents" as used herein are expressed as mg catechin equivalents / g raw material or g catechin equivalents / L raw material. The terms "GAE" or "gallic acid equivalents" as used herein are expressed as mg gallic acid equivalents / g extract derived from sugar cane or g gallic acid equivalents / L extract derived from sugar cane. As measures of total polyphenol content, the terms "CE", "catechin equivalents", "GAE" and "gallic acid equivalents" are equivalent and may be used interchangeably herein.
[0132] As used herein, the term "free amino acid" refers to an amino acid that is a single molecule and is not structurally linked to peptide bonds with other amino acids.
[0133] As used herein, the term "sugar cane derived products" refers to products of the sugar cane milling and refining process, including but not limited to sugar, molasses, massecuite, bagasse, first pressed juice, mill mud, clarified cane juice, clarified syrup, spent honey, golden syrup, inclusions, cane peelings, cane leaves, growth cones, pulp and dunder and combinations thereof. Dregs refers to the residue produced when a product such as sugar or molasses is fermented to produce, for example, ethanol. Bagasse is also known as biodunder, stillage or vinasse. As used herein, the terms "dregs", "biodunder", "stillage" and "vinasse" are equivalent and can be used interchangeably.
[0134] Throughout the specification, various aspects and components of the present invention can be presented in range format. It is for convenience to include range format, and range format should not be interpreted as an inflexible limitation on the scope of the present disclosure. Therefore, unless otherwise specified, the description of the range should be deemed to have clearly disclosed all possible sub-ranges and single numerical values within the range. For example, unless an integer is required or an integer is implied from the context, the description of a range such as from 1 to 5 should be deemed to have clearly disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 5, from 3 to 5, and single and partial numbers (such as 1, 2, 3, 4, 5, 5.5 and 6) within the listed range. Regardless of the breadth of the disclosed range, this applies. Where specific values are required, these specific values will be indicated in the specification.
[0135] The terms "extract derived from sugar cane of the (present) disclosure", "extract of the (present) disclosure", "sugar cane extract of the (present) disclosure", "sugar cane extract" and "extract" are used interchangeably herein.
[0136] Throughout the specification, the word "comprise" or variations such as "comprising" or "including" will be understood to imply the inclusion of stated elements, integers or steps, or groups of elements, integers or steps, but not the exclusion of any other elements, integers or steps, or groups of elements, integers or steps.
[0137] General Technology
[0138] Exemplary process flow for producing extracts derived from sugar cane
[0139] An appropriate process flow for producing an extract derived from sugar cane can be determined by a skilled artisan.
[0140] Feedstock for extraction processes
[0141] After mechanical harvesting of sugar cane, the cane is transported to the mill and crushed between sawtooth rollers. The crushed cane is then pressed to extract the raw sugar juice and the cane leaf fibrous material called bagasse (usually used as fuel). The raw juice is then heated to its boiling point to extract any impurities, and then lime and bleaching agents are added and the mill mud is removed. The raw juice is further heated under vacuum to concentrate and increase the Brix value. The concentrated syrup is spread to produce a large amount of sugar crystals and a viscous syrup called molasses. The two are separated by a centrifuge, and the molasses waste stream is usually collected for use as a low-grade animal feed.
[0142] The extract produced according to the process of the present disclosure can be an extract of sugar cane or an extract from any sugar cane derived product, including those produced during the sugar cane milling process, the sugar cane refining process, and other processes using sugar cane products.
[0143] As defined above, the term "sugar cane derived product" refers to the products of the sugar cane milling and refining process, including but not limited to molasses, massecuite, bagasse, virgin juice, mill mud, clarified sugar cane juice, clarified syrup, spent honey, golden molasses, inclusions, cane strippings, cane leaves, growth cones, cane pulp and dregs, and combinations thereof. In one embodiment, the sugar cane derived product is molasses or dregs. In one embodiment, the sugar cane derived product is a combination of molasses and dregs. In another embodiment, the sugar cane derived product is molasses. In another embodiment, the sugar cane derived product is massecuite. In another embodiment, the sugar cane derived product is dregs. In another embodiment, the sugar cane derived product is a combination of molasses and dregs. In another embodiment, the sugar cane derived product is bagasse. In another embodiment, the sugar cane derived product is virgin juice. In another embodiment, the sugar cane derived product is mill mud. In another embodiment, the sugar cane derived product is clarified sugar cane juice. In another embodiment, the sugar cane derived product is clarified syrup. In another embodiment, the sugar cane derived product is spent honey. In another embodiment, the sugar cane derived product is golden syrup. In another embodiment, the sugar cane derived product is inclusions. In another embodiment, the sugar cane derived product is sugar cane peels. In another embodiment, the sugar cane derived product is cane leaves. In another embodiment, the sugar cane derived product is growth cones. In another embodiment, the sugar cane derived product is cane pulp.
[0144] Sugar cane derived products typically include a complex mixture of substances including, but not limited to, polyphenols, phytosterols, monosaccharides, disaccharides, oligosaccharides, polysaccharides, organic acids, amino acids, peptides, proteins, vitamins and minerals.
[0145] As will be appreciated by the skilled artisan, polyphenols are compounds characterized by the presence of multiple phenolic structural units. Polyphenols can be divided into subgroups according to their chemical structure. Examples of subgroups of polyphenols include, but are not limited to, flavonoids (including flavones, flavanols, flavonols), hydroxybenzoic acids, hydroxycinnamic acids, catechins, proanthocyanidins, anthocyanidins, stilbenes, lignans, and phenolic acids. Polyphenols of sugar cane derived products also include conjugates, such as glycosides, glucosides, galactosides, galacturonans, ethers, esters, arabinosides, sulfates, phosphates, five-carbon aldoses (xylose, arabinose) and six-carbon aldoses.
[0146] An exemplary process flow for producing an extract according to the present disclosure is provided below. The exemplary process flow involves an extraction step. Figure 1 An exemplary process flow for molasses as a sugarcane derived product is depicted.
[0147] In one process flow for producing the extracts of the present disclosure, a sugar cane-derived product is used as a feedstock and mixed with a suitable solvent, such as ethanol, to form an extraction mixture.
[0148] The skilled artisan will appreciate that in order to facilitate mixing of the sugar cane derived product with a suitable solvent such as ethanol, it may be necessary to mix the sugar cane derived product with a liquid such as, but not limited to, water, and / or heat the sugar cane derived product to achieve a desired viscosity. In one embodiment of the present disclosure, where the sugar cane derived product is molasses, for example, the molasses may be mixed with a liquid such as water to achieve a desired viscosity. The sugar cane derived product, mixed with or without a liquid, may be heated to reduce viscosity.
[0149] For sugar cane derived products including solid materials such as bagasse, inclusions, and cane peels, it is desirable to mix or homogenize the product with a liquid, such as, but not limited to, water, prior to mixing with ethanol to form an extraction mixture. A skilled person can readily determine the amount of liquid to mix or homogenize with the sugar cane derived product in order to obtain a sugar cane derived product having a viscosity suitable for mixing with ethanol to form an extraction mixture.
[0150] In one embodiment, the sugar cane derived product will have a viscosity of about 100 centipoise or less. In another embodiment, the sugar cane derived product will have a viscosity between about 50 and about 100 centipoise. In another embodiment, the sugar cane derived product will have a viscosity between about 50 and about 80 centipoise.
[0151] The high viscosity of molasses is a result of the high content of total solids, especially soluble sugar compounds, and is typically measured by determining the Brix. In one embodiment, the sugar cane derived product may have a Brix of about 10° to about 80°. In another embodiment, the sugar cane derived product may have a Brix of about 20° to about 70°. In another embodiment, the sugar cane derived product may have a Brix of about 20° to about 50°. In another embodiment, the sugar cane derived product may have a Brix of about 30° to about 60°. In another embodiment, the sugar cane derived product may have a Brix of about 40° to about 50°.
[0152] To extract compounds such as polyphenols, the sugar cane-derived product is mixed with ethanol to form an extraction mixture. In one embodiment, the extraction mixture includes at least about 50% v / v ethanol. In another embodiment, the extraction mixture includes at least about 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84% or 85% v / v ethanol.
[0153] In order to remove the color of the supernatant while minimizing the reduction of polyphenols, the optimal concentration of ethanol in the extraction mixture is about 70% to about 85% v / v. In one embodiment, the extraction mixture includes about 65% to about 75% v / v ethanol. In one embodiment, the extraction mixture includes about 70% to about 80% v / v ethanol. In one embodiment, the extraction mixture includes about 70% to about 75% v / v ethanol. In one embodiment, the extraction mixture includes about 75% to about 80% v / v ethanol. In one embodiment, the extraction mixture includes about 80% to about 85% v / v ethanol. In one embodiment, the extraction mixture includes about 80% to about 83% v / v ethanol. In one embodiment, the extraction mixture includes about 65% v / v ethanol. In another embodiment, the extraction mixture includes about 70% v / v ethanol. In another embodiment, the extraction mixture includes about 75% v / v ethanol. In another embodiment, the extraction mixture includes about 80% v / v ethanol. In another embodiment, the extraction mixture includes about 83% v / v ethanol. In another embodiment, the extraction mixture includes about 85% v / v ethanol.
[0154] In the process flow of the present disclosure, it may be desirable to avoid extreme pH in the extraction mixture, as extreme pH may have a deleterious effect on the components of the extraction mixture. Thus, in one embodiment, the pH of the extraction mixture is about pH 4 to about pH 7.5. In another embodiment, the pH of the extraction mixture is about pH 4 to about pH 6. In another embodiment, the pH of the extraction mixture is about pH 4 to about pH 5.
[0155] After the precipitate is formed in the extraction mixture, the precipitate may be removed from the mixture by any suitable method known in the art. For example, the precipitate may be removed by centrifugation to obtain a supernatant. Alternatively, the precipitate may be allowed to settle for a sufficient period of time, such as by gravity settling, to allow a supernatant to be obtained while retaining the precipitate. The skilled artisan will appreciate that other techniques, such as filtration, may be used alone or in combination with centrifugation or settling to produce an extract derived from sugar cane.
[0156] Once the supernatant is obtained, ethanol can be removed using techniques known in the art. By way of non-limiting example, ethanol can be removed from the supernatant by evaporation (e.g., by using a rotary evaporator with a hot bath of about 45 ° C or higher). In some cases, it may be desirable to further remove water from the supernatant to increase the Brix value of the supernatant. In one embodiment, the process provides an extract with at least about 60 ° Bx (Brix). In some cases, the Bx value of the extract derived from sugar cane is at least about 65 ° Bx. In some cases, the Bx value of the extract derived from sugar cane is at least about 70 ° Bx. In some cases, the Bx value of the extract derived from sugar cane is about 60-65 ° Bx. In some cases, the Bx value of the extract derived from sugar cane is about 65-70 ° Bx. In some cases, the Bx value of the extract derived from sugar cane is about 64-65 ° Bx. In some cases, the Bx value of the extract derived from sugar cane is about 70-75 ° Bx.
[0157] In one embodiment of the process flow of the present disclosure, the supernatant comprising ethanol or the extract derived from sugar cane from which ethanol has been removed is used without further treatment. Alternatively, the supernatant comprising ethanol or the extract derived from sugar cane from which ethanol has been removed can be purified or fractionated.
[0158] The purification step may remove, for example, pigment impurities that contribute to the color of the extract derived from sugar cane, etc. By way of non-limiting example, the supernatant or the extract derived from sugar cane may be subjected to a purification step comprising one or more of membrane filtration, size exclusion chromatography, ion exchange chromatography, and / or hydrophobic interaction chromatography. In one embodiment, the supernatant or the extract may be subjected to hydrophobic interaction chromatography.
[0159] Several techniques are known in the art for separating compounds based on size. For example, it is known in the art that components of a supernatant or extract that fall within a specific molecular weight range can be separated by size exclusion methods such as gel permeation chromatography or ultrafiltration.
[0160] The separation of the components of the supernatant and / or the extract derived from sugar cane may also be achieved using a chromatographic technique or a combination of techniques. In one embodiment, the chromatographic techniques include, but are not limited to, ion exchange chromatography, hydrophobic interaction chromatography, liquid chromatography-mass spectrometry (LCMS), and / or HPLC. The skilled artisan will readily determine the appropriate stationary phase and mobile phase for any chromatographic technique used. The skilled artisan will also readily determine the appropriate elution technique. The chromatographic technique may utilize a graded elution by gradually increasing the pH or using an appropriate solvent.
[0161] In one embodiment, the supernatant and / or the extract derived from sugar cane is subjected to one or more chromatographic techniques. In one embodiment, the supernatant and / or the extract derived from sugar cane is subjected to hydrophobic interaction chromatography. In one embodiment, the supernatant and / or the extract derived from sugar cane is subjected to hydrophobic interaction chromatography using sephadex LH-20, XAD or FPX66 resin. In one embodiment, the supernatant and / or the extract derived from sugar cane is passed through a sephadex LH-20 resin. In one embodiment, the supernatant and / or the extract derived from sugar cane is passed through a XAD resin. In one embodiment, the supernatant and / or the extract derived from sugar cane is passed through a FPX66 resin.
[0162] The supernatant and / or the extract derived from sugar cane may also be processed by standard techniques such as, but not limited to, microfiltration, reverse osmosis, gel permeation, vacuum evaporation, and freeze drying, spray drying, and / or tunnel drying.
[0163] Another exemplary process flow for producing an extract according to the present disclosure is provided below. This exemplary process flow involves multiple filtration steps. Figure 2 An exemplary process flow for using bagasse as a sugarcane derived product is depicted.
[0164] The bagasse is allowed to sit overnight (typically eight hours) in a V-bottom tank. The supernatant is then subjected to a number of filtration steps. The skilled person will appreciate that various filtration steps (e.g., microfiltration or ultrafiltration) may be performed and the skilled person will readily determine the appropriate filtration step.
[0165] In one embodiment, the supernatant is sequentially microfiltered. In one embodiment, the supernatant is sequentially filtered through: (i) a 5 micron filter; (ii) a 1 micron filter; (iii) a 0.5 micron filter; and (iv) a 0.1 micron filter. The skilled person will appreciate that various filters can be used in the process flow to remove desired sediments and insoluble materials. Exemplary filters are stainless steel filters, ceramic filters, and fiber filters.
[0166] The filtered supernatant is then concentrated to remove water, thereby providing an extract. Any method for removing water can be used, including, for example, heat exchange and evaporation. In one embodiment, the filtered supernatant is concentrated in a heat exchanger to remove water until the desired Brix level of the extract is reached. In one embodiment, the process provides an extract with at least about 40 ° Bx. In one embodiment, the Bx value of the extract is at least about 50 ° Bx. In one embodiment, the Bx value of the extract is at least about 55 ° Bx. In one embodiment, the Bx value of the extract is at least about 60 ° Bx. In one embodiment, the Bx value of the extract is at least about 70 ° Bx. In one embodiment, the Bx value of the extract is about 45-55 ° Bx. In one embodiment, the Bx value of the extract is about 50 ° Bx. In one embodiment, the Bx value of the extract is about 50 ° Bx. In one embodiment, the Bx value of the extract is about 50-55 ° Bx. In one embodiment, the Bx value of the extract is about 55-60 ° Bx. In one embodiment, the Bx value of the extract is about 50-70 ° Bx. Another exemplary process for producing an extract according to the present invention is provided below. Figure 3 An exemplary process flow for a combination of bagasse and molasses as sugarcane derived products is depicted.
[0167] Sugarcane mill molasses is mixed with stationary bagasse (as described above) and stirred thoroughly to provide a mixture with a desired Brix level. It will be appreciated by the skilled person that a liquid (such as, but not limited to, water) may be added to facilitate the mixing of the molasses with the bagasse. The liquid may be added to the molasses and / or bagasse before the molasses and bagasse are combined, or the liquid may be added to the combined molasses and bagasse. In addition, heating may be performed to achieve the desired viscosity. In one embodiment, the combined mixture of molasses and bagasse is about 50-55°Bx. In one embodiment, the combined mixture of molasses and bagasse is about 50°Bx. In one embodiment, the combined mixture of molasses and bagasse is about 55°Bx. In one embodiment, the combined mixture of molasses and bagasse is at least about 50°Bx. In one embodiment, the combined mixture of molasses and bagasse is at least about 60°Bx. In one embodiment, the combined mixture of molasses and bagasse is at least about 70°Bx.
[0168] The combined mixture of molasses and dregs is maintained at a constant temperature (e.g., between 20-25° C.), ethanol (e.g., 95% food grade ethanol) is added and stirred to ensure that the ethanol is evenly and quickly dispersed. Ethanol is added until the desired ethanol level is reached. The desired ethanol content can be from about 50% v / v to about 90% v / v. The desired ethanol content can be about 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90% v / v. In one embodiment, the desired ethanol level is at least about 60% v / v. In one embodiment, the desired ethanol level is at least about 70% v / v. In one embodiment, the desired ethanol level is at least about 80% v / v. In one embodiment, the desired ethanol level is about 60-70% v / v. In one embodiment, the desired ethanol level is about 70-80% v / v. In one embodiment, the desired ethanol level is about 75% v / v. In one embodiment, the desired ethanol level is about 76% v / v.
[0169] The addition and mixing of ethanol may result in the formation of a gelatinous precipitate. The precipitate in the mixture is allowed to settle and the supernatant is removed by, for example, decantation and / or filtration. In one embodiment, the supernatant is decanted. In one embodiment, the supernatant is filtered. In one embodiment, the supernatant is decanted and filtered.
[0170] Ethanol is removed from the supernatant to provide an extract. Any method for removing ethanol can be used, including, for example, heat exchange and evaporation. In one embodiment, ethanol is removed by evaporation until the desired Brix level of the extract is reached. In one embodiment, the process provides an extract with at least about 50°Bx. In one embodiment, the Bx value of the extract is at least about 60°Bx. In one embodiment, the Bx value of the extract is at least about 70°Bx. In one embodiment, the Bx value of the extract is at least about 80°Bx. In one embodiment, the Bx value of the extract is about 50-60°Bx. In one embodiment, the Bx value of the extract is about 60-70°Bx. In one embodiment, the Bx value of the extract is about 70-80°Bx. In one embodiment, the Bx value of the extract is about 65-75°Bx. In one embodiment, the Bx value of the extract is about 75°Bx. In one embodiment, the Bx value of the extract is at least about 70°Bx.
[0171] Extract derived from sugar cane
[0172] As noted above, extracts derived from sugar cane typically include a complex mixture of substances including, but not limited to, polyphenols, phytosterols, oligosaccharides, polysaccharides, monosaccharides, disaccharides, organic acids, amino acids, peptides, proteins, vitamins and minerals.
[0173] In one embodiment, the sugar cane-derived extract of the present disclosure includes at least about 10 CE g / L of polyphenols or at least about 150 mg CE / g of polyphenols. As explained above, the term "CE" or "catechin equivalent" is a measure of total phenolic content, expressed as mg catechin equivalents / g of extract derived from sugar cane or g catechin equivalents / L of extract derived from sugar cane.
[0174] In one embodiment, the sugar cane-derived extract of the present disclosure comprises at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 CE g / L of polyphenols.
[0175] In one embodiment, the sugar cane-derived extract of the present disclosure comprises at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 250, 275, 300, 325, 350, 375, 400, 425, 450, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, or 800 mg CE / g of polyphenols.
[0176] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 1 CE g / L to about 50 CE g / L of polyphenols or about 10 CE mg / g to about 500 CE mg / g of polyphenols.
[0177] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 1 CE g / L to about 25 CE g / L of polyphenols or about 10 CE mg / g to about 250 CE mg / g of polyphenols.
[0178] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 1 CE g / L to about 10 CE g / L of polyphenols or about 10 CE mg / g to about 100 CE mg / g of polyphenols.
[0179] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 1 CE g / L to about 5 CE g / L of polyphenols or about 10 CE mg / g to about 100 CE mg / g of polyphenols.
[0180] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 5 CE g / L to about 50 CE g / L of polyphenols or about 50 CE mg / g to about 500 CE mg / g of polyphenols.
[0181] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 5 CE g / L to about 25 CE g / L of polyphenols or about 50 CE mg / g to about 250 CE mg / g of polyphenols.
[0182] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 5 CE g / L to about 10 CE g / L of polyphenols or about 50 CE mg / g to about 100 CE mg / g of polyphenols.
[0183] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 10 CE g / L to about 100 CE g / L of polyphenols or about 100 CE mg / g to about 1000 CE mg / g of polyphenols.
[0184] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 10 CE g / L to about 90 CE g / L of polyphenols or about 100 CE mg / g to about 900 CE mg / g of polyphenols.
[0185] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 10 CE g / L to about 80 CE g / L of polyphenols or about 100 CE mg / g to about 800 CE mg / g of polyphenols.
[0186] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 10 CE g / L to about 70 CE g / L of polyphenols or about 100 CE mg / g to about 700 CE mg / g of polyphenols.
[0187] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 10 CE g / L to about 60 CE g / L of polyphenols or about 100 CE mg / g to about 600 CE mg / g of polyphenols.
[0188] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 10 CE g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0189] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 10 CE g / L to about 25 CE g / L of polyphenols or about 100 CE mg / g to about 250 CE mg / g of polyphenols.
[0190] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 15 CE g / L to about 50 CE g / L of polyphenols or about 150 CE mg / g to about 500 CE mg / g of polyphenols.
[0191] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 15 CE g / L to about 25 CE g / L of polyphenols or about 150 CE mg / g to about 250 CE mg / g of polyphenols.
[0192] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 10 CE g / L to about 70 CE g / L of polyphenols or about 100 CE mg / g to about 700 CE mg / g of polyphenols.
[0193] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 10 CE g / L to about 60 CE g / L of polyphenols or about 100 CE mg / g to about 600 CE mg / g of polyphenols.
[0194] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 10 CE g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0195] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 15 CE g / L to about 40 CE g / L of polyphenols or about 150 CE mg / g to about 400 CE mg / g of polyphenols.
[0196] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 20 CE g / L to about 30 CE g / L of polyphenols or about 200 CE mg / g to about 300 CE mg / g of polyphenols.
[0197] In one embodiment, the sugar cane-derived extract of the present disclosure comprises about 20 CE g / L to about 27 gCE / L of polyphenols or about 200 CE mg / g to about 270 CE mg / g of polyphenols.
[0198] In one embodiment, the sugar cane-derived extract of the present disclosure comprises about 27 CE g / L to about 35 gCE / L of polyphenols or about 270 CE mg / g to about 350 CE mg / g of polyphenols.
[0199] In one embodiment, the sugar cane-derived extract of the present disclosure comprises about 35 CE g / L to about 40 g CE / L of polyphenols or about 350 CE mg / g to about 400 CE mg / g of polyphenols.
[0200] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 40 CE g / L to about 50 g CE / L of polyphenols or about 400 CE mg / g to about 500 CE mg / g of polyphenols.
[0201] In one embodiment, the sugar cane-derived extract of the present disclosure comprises about 45 CE g / L to about 50 g CE / L of polyphenols or about 450 CE mg / g to about 500 CE mg / g of polyphenols.
[0202] The extract derived from sugar cane of the present disclosure may contain flavonoid polyphenols. The extract derived from sugar cane may contain any amount of flavonoids. In one embodiment, the extract derived from sugar cane of the present disclosure includes at least about 1 CE g / L of flavonoids or at least about 10 CE mg / g of flavonoids.
[0203] In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 1CE g / L to about 15CE g / L of flavonoids or about 10CE mg / g to about 150CE mg / g of flavonoids. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 3CE g / L to about 10CE g / L of flavonoids or about 30CE mg / g to about 100CE mg / g of flavonoids. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 5CE g / L to about 8CE g / L of flavonoids or about 50CE mg / g to about 80CE mg / g of flavonoids. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 6CE g / L to about 8CE g / L of flavonoids or about 60CE mg / g to about 80CE mg / g of flavonoids. In one embodiment, the sugar cane-derived extract of the present disclosure comprises about 6.5 CE g / L to about 7.5 CE g / L of flavonoids or about 65 CE mg / g to about 75 CE mg / g of flavonoids.
[0204] The extract derived from sugar cane of the present disclosure may contain proanthocyanidin polyphenols. The extract derived from sugar cane may contain any amount of proanthocyanidins. In one embodiment, the extract derived from sugar cane of the present disclosure includes at least about 1.5CE g / L of proanthocyanidins or at least about 15CE mg / g of proanthocyanidins. In one embodiment, the extract derived from sugar cane of the present disclosure includes at least about 1.8CE g / L of proanthocyanidins or at least about 18CE mg / g of proanthocyanidins. In one embodiment, the extract derived from sugar cane of the present disclosure includes about 1.5CE g / L to about 2.5CE g / L of proanthocyanidins or about 15CE mg / g to about 25CE mg / g of proanthocyanidins. In one embodiment, the extract derived from sugar cane of the present disclosure includes about 1.8CE g / L to about 2.2CE g / L of proanthocyanidins or about 18CE mg / g to about 22CE mg / g of proanthocyanidins.
[0205] The polyphenols derived from the extract of sugar cane of the present disclosure include, but are not limited to, syringic acid, chlorogenic acid, caffeic acid, vanillin, sinapinic acid, p-coumaric acid, ferulic acid, gallic acid, vanillic acid, diosmin, diosmetin, apigenin, vitexin, orientin, isoorientin, tangerin, triticum vulgare, (+)-catechin, (-)-catechin gallate, (-)-epicatechin, quercetin, kaempferol, myricetin, rutin, schaftoside, isoschaftoside, luteolin, genistein and / or one or more of their derivatives. The polyphenols derived from the extract of sugar cane of the present disclosure may also include, but are not limited to, one or more of hydroxycinnamic acid, isoorientin, tangerin, neocarlinoside, isoorientin, vicenin and / or their derivatives.
[0206] Polyphenols derived from extracts of sugar cane also include conjugates such as glycosides, glucosides, galactosides, galacturones, ethers, esters, arabinosides, sulfates, phosphates, five-carbon aldoses (xylose, arabinose) and six-carbon aldoses.
[0207] In one embodiment, the extract derived from sugar cane of the present disclosure includes syringic acid, chlorogenic acid, caffeic acid, vanillin, sinapinic acid, diosmin, diosmetin, apigenin, vitexin, orientin, isoorientin, anacardin, triticiflavin, and / or their derivatives.
[0208] In one embodiment, the sugar cane-derived extract of the present disclosure includes syringic acid, chlorogenic acid, diosmin, and / or derivatives thereof.
[0209] In one embodiment, the extract derived from sugar cane of the present disclosure includes syringic acid. In one embodiment, the extract derived from sugar cane of the present disclosure includes chlorogenic acid. In one embodiment, the extract derived from sugar cane of the present disclosure includes diosmin. In one embodiment, the extract derived from sugar cane of the present disclosure includes caffeic acid. In one embodiment, the extract derived from sugar cane of the present disclosure includes vanillin. In one embodiment, the extract derived from sugar cane of the present disclosure includes sinapinic acid. In one embodiment, the extract derived from sugar cane of the present disclosure includes vitexin. In one embodiment, the extract derived from sugar cane of the present disclosure includes p-coumaric acid. In one embodiment, the extract derived from sugar cane of the present disclosure includes ferulic acid. In one embodiment, the extract derived from sugar cane of the present disclosure includes gallic acid. In one embodiment, the extract derived from sugar cane of the present disclosure includes vanillic acid. In one embodiment, the extract derived from sugar cane of the present disclosure includes diosmetin. In one embodiment, the extract derived from sugar cane of the present disclosure includes apigenin. In one embodiment, the extract derived from sugar cane of the present disclosure includes orientin. In one embodiment, the extract derived from sugar cane of the present disclosure includes isoorientin. In one embodiment, the extract derived from sugar cane of the present disclosure includes dansaflavin. In one embodiment, the extract derived from sugar cane of the present disclosure includes tricholin. In one embodiment, the extract derived from sugar cane of the present disclosure includes (+)-catechin. In one embodiment, the extract derived from sugar cane of the present disclosure includes (-)-catechin gallate. In one embodiment, the extract derived from sugar cane of the present disclosure includes (-)-epicatechin. In one embodiment, the extract derived from sugar cane of the present disclosure includes quercetin. In one embodiment, the extract derived from sugar cane of the present disclosure includes kaempferol. In one embodiment, the extract derived from sugar cane of the present disclosure includes myricetin. In one embodiment, the extract derived from sugar cane of the present disclosure includes rutin. In one embodiment, the extract derived from sugar cane of the present disclosure includes schaftoside. In one embodiment, the extract derived from sugar cane of the present disclosure includes isoschaftoside. In one embodiment, the extract derived from sugar cane of the present disclosure includes luteolin. In one embodiment, the extract derived from sugar cane of the present disclosure includes genistin. In one embodiment, the extract derived from sugar cane of the present disclosure includes hydroxycinnamic acid. In one embodiment, the extract derived from sugar cane of the present disclosure includes isoorientin. In one embodiment, the extract derived from sugar cane of the present disclosure includes hydrangeoflavone. In one embodiment, the extract derived from sugar cane of the present disclosure includes neoephrine. In one embodiment, the extract derived from sugar cane of the present disclosure includes isovitexin.In one embodiment, the sugar cane-derived extract of the present disclosure includes vetacamine.
[0210] In one embodiment, syringic acid, chlorogenic acid, and diosmin are the three most abundant polyphenols of the sugar cane-derived extract of the present disclosure.
[0211] In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 5-20 μg / g dry weight of syringic acid. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 7-15 μg / g dry weight of syringic acid. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10-12 μg / g dry weight of syringic acid. In one embodiment, the extract derived from sugar cane of the present disclosure, when present, comprises about 10.9 μg / g dry weight of syringic acid. The extract derived from sugar cane may be in the form of a syrup.
[0212] In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 50-200 μg / g dry weight of syringic acid. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 90-130 μg / g dry weight of syringic acid. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 100-120 μg / g dry weight of syringic acid. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 107 μg / g dry weight of syringic acid. The extract derived from sugar cane may be in powder form.
[0213] In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 1-15 μg / g dry weight of chlorogenic acid. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 3-10 μg / g dry weight of chlorogenic acid. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 5-8 μg / g dry weight of chlorogenic acid. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 6.53 μg / g dry weight of chlorogenic acid. The extract derived from sugar cane may be in the form of a syrup.
[0214] In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 30-150 μg / g dry weight of chlorogenic acid. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 60-90 μg / g dry weight of chlorogenic acid. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 70-80 μg / g dry weight of chlorogenic acid. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 74 μg / g dry weight of chlorogenic acid. The extract derived from sugar cane may be in powder form.
[0215] In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10-30 μg / g dry weight of diosmin. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 15-25 μg / g dry weight of diosmin. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 18-21 μg / g dry weight of diosmin. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 19-45 μg / g dry weight of diosmin. The extract derived from sugar cane can be in the form of a syrup.
[0216] In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 100-300 μg / g dry weight of diosmin. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 190-260 μg / g dry weight of diosmin. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 210-240 μg / g dry weight of diosmin. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 227 μg / g dry weight of diosmin. The extract derived from sugar cane may be in powder form.
[0217] In one embodiment, the extract derived from sugar cane of the present disclosure includes about 7-15 μg / g dry weight of syringic acid, and / or about 4-9 μg / g dry weight of chlorogenic acid, and / or about 0.1-0.5 μg / g dry weight of caffeic acid, about 0.05-0.3 μg / g dry weight of vanillin, and / or about 0.1-0.3 μg / g dry weight of sinapinic acid, and / or about 15-25 μg / g dry weight of diosmin, and / or about 0.1-0.4 μg / g dry weight of orientin, and / or about 0.4-0.9 μg / g dry weight of dansoflavone, and / or about 0.05-0.3 μg / g dry weight of diosmin. The extract derived from sugar cane may be in the form of a syrup.
[0218] In one embodiment, the extract derived from sugar cane of the present disclosure includes about 10-12 μg / g dry weight of syringic acid, and / or about 5-8 μg / g dry weight of chlorogenic acid, and / or about 0.2-0.4 μg / g dry weight of caffeic acid, and / or about 0.1-0.2 μg / g dry weight of vanillin, and / or about 0.1-0.25 μg / g dry weight of sinapinic acid, and / or about 18-21 μg / g dry weight of diosmin, and / or about 0.2-0.3 μg / g dry weight of orientin, and / or about 0.5-0.8 μg / g dry weight of dansoflavone, and / or about 0.1-0.2 μg / g dry weight of diosmin. The extract derived from sugar cane may be in the form of a syrup.
[0219] In one embodiment, the extract derived from sugar cane of the present disclosure includes about 10.9 μg / g dry weight of syringic acid, and / or about 6.53 μg / g dry weight of chlorogenic acid, and / or about 0.29 μg / g dry weight of caffeic acid, and / or about 0.153 μg / g dry weight of vanillin, and / or about 0.18 μg / g dry weight of sinapinic acid, and / or about 19.45 μg / g dry weight of diosmin, and / or about 0.245 μg / g dry weight of orientin, and / or about 0.69 μg / g dry weight of dansoflavone, and / or about 0.15 μg / g dry weight of diosmin. The extract derived from sugar cane may be in the form of a syrup.
[0220] In one embodiment, the extract derived from sugar cane of the present disclosure includes about 90-130 μg / g dry weight of syringic acid, and / or about 60-90 μg / g dry weight of chlorogenic acid, and / or about 4-10 μg / g dry weight of caffeic acid, and / or about 1-4 μg / g dry weight of vanillin, about 1-3 μg / g dry weight of sinapinic acid, and / or about 190-260 μg / g dry weight of diosmin, and / or about 3-7 μg / g dry weight of orientin, and / or 3-8 μg / g dry weight of dansoflavone, and / or about 0.05-0.3 μg / g dry weight of diosmin. The extract derived from sugar cane may be in powder form.
[0221] In one embodiment, the extract derived from sugar cane of the present disclosure includes about 100-120 μg / g dry weight of syringic acid, and / or about 70-80 μg / g dry weight of chlorogenic acid, and / or about 6-8 μg / g dry weight of caffeic acid, about 2-3 μg / g dry weight of vanillin, and / or about 1.5-2.5 μg / g dry weight of sinapinic acid, and / or about 210-240 μg / g dry weight of diosmin, about 4-5 μg / g dry weight of orientin, 4-6 μg / g dry weight of dansoflavone, and / or about 0.1-0.2 μg / g dry weight of diosmin. The extract derived from sugar cane can be in powder form.
[0222] In one embodiment, the extract derived from sugar cane of the present disclosure includes about 107 μg / g dry weight of syringic acid, and / or about 74 μg / g dry weight of chlorogenic acid, and / or about 7.5 μg / g dry weight of caffeic acid, and / or about 2 μg / g dry weight of vanillin, and / or about 1.7 μg / g dry weight of sinapinic acid, and / or about 227 μg / g dry weight of diosmin, and / or about 4.5 μg / g dry weight of orientin, 5.2 μg / g dry weight of dansoflavone, and / or about 0.16 μg / g dry weight of diosmin. The extract derived from sugar cane may be in powder form.
[0223] The extract derived from sugar cane of the present disclosure may include a series of organic acids naturally found in sugar cane. These organic acids may include but are not limited to (cis and trans) aconitic acid, oxalic acid, citric acid, lactic acid, tartaric acid, glycolic acid, succinic acid, citric acid, malic acid, fumaric acid and shikimic acid. In one embodiment, the level of citric acid and malic acid contained in the extract derived from sugar cane is higher than other organic acids. In another embodiment, the extract derived from sugar cane includes low amounts of oxalic acid, citric acid, tartaric acid, glycolic acid, succinic acid and citric acid. In another embodiment, the two most abundant organic acids in the extract derived from sugar cane are trans-aconitic acid and cis-aconitic acid.
[0224] The extract derived from sugar cane of the present disclosure may contain trans-aconitic acid and / or cis-aconitic acid. In one embodiment, the extract derived from sugar cane of the present disclosure includes trans-aconitic acid in an amount of about 10,000-40,000 mg / kg and / or cis-aconitic acid in an amount of about 3,000-7,000 mg / kg. In one embodiment, the extract derived from sugar cane of the present disclosure includes trans-aconitic acid in an amount of about 17,000-30,000 mg / kg and / or cis-aconitic acid in an amount of about 4,000-6,500 mg / kg. In one embodiment, the extract derived from sugar cane of the present disclosure may include trans-aconitic acid in an amount of about 20,000-25,000 mg / kg and / or cis-aconitic acid in an amount of about 5,000-5,500 mg / kg.
[0225] The sugar cane-derived extract of the present disclosure may comprise amino acids. In one embodiment, the total amino acid level of the sugar cane-derived extract of the present disclosure is about 50,000-80,000 μg per gram, or about 60,000-70,000 μg per gram, or about 65,000 μg per gram. In one embodiment, about 10-40% of the total amino acids are essential amino acids. In one embodiment, about 15-30% of the total amino acids are essential amino acids. In one embodiment, about 20-25% of the total amino acids are essential amino acids.
[0226] The sugar cane-derived extract of the present disclosure may contain free amino acids. In one embodiment, the sugar cane-derived extract of the present disclosure includes about 10,000-50,000 μg of free amino acids per gram. In one embodiment, the sugar cane-derived extract of the present disclosure may contain about 20,000-35,000 μg of free amino acids per gram. The sugar cane-derived extract of the present disclosure may contain about 25,000-30,000 μg of free amino acids per gram.
[0227] As defined above, the term "free amino acid" as used herein refers to an amino acid that is a single molecule and is not structurally linked to peptide bonds with other amino acids.
[0228] The extract derived from sugar cane of the present disclosure may contain leucine, a branched chain essential amino acid. In one embodiment, the concentration of leucine in the extract derived from sugar cane is about 1-5 mM, or about 1.5-4 mM, or about 2-3 mM. In one embodiment, the amount of leucine in the extract derived from sugar cane is about 1,000-20,000 μg per gram, or about 1,000-10,000 μg per gram, or about 1,000-5,000 μg per gram, or about 1,000-2,000 μg per gram, or about 5,000-10,000 μg per gram, or about 10,000-20,000 μg per gram.
[0229] The sugar cane-derived extracts of the present disclosure may contain minerals. In one embodiment, the sugar cane-derived extracts contain minerals naturally found in sugar cane. In one embodiment, the sugar cane-derived extracts contain one or more minerals including, but not limited to, potassium, sodium, calcium, magnesium, iron, zinc, selenium, and chromium.
[0230] In one embodiment, the extract derived from sugar cane comprises minerals bound to polyphenols. In one embodiment, the extract derived from sugar cane comprises divalent ions bound to polyphenols. In one embodiment, the extract derived from sugar cane comprises calcium, magnesium and / or iron bound to polyphenols. In one embodiment, the extract derived from sugar cane comprises iron bound to polyphenols.
[0231] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 20,000-32,000 mg potassium per kilogram, and / or about 300-600 mg sodium per kilogram, and / or about 800-1,300 mg calcium per kilogram, and / or about 3,000-6,000 mg magnesium per kilogram, and / or about 40-90 mg iron per kilogram, and / or about 3-10 mg zinc per kilogram, and / or about 500-900 μg selenium per kilogram, and / or about 1,000-1,600 μg chromium per kilogram. The sugar cane-derived extract may be in the form of a syrup.
[0232] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 25,000-27,000 mg potassium per kilogram, and / or about 400-500 mg sodium per kilogram, and / or about 1,000-1,200 mg calcium per kilogram, and / or about 4,000-5,500 mg magnesium per kilogram, and / or about 55-75 mg iron per kilogram, and / or about 5.5-7.5 mg zinc per kilogram, and / or about 700-850 μg selenium per kilogram, and / or about 1,200-1,400 μg chromium per kilogram. The sugar cane-derived extract may be in the form of a syrup.
[0233] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 26,000 mg potassium per kilogram, and / or about 450 mg sodium per kilogram, and / or about 1,090 mg calcium per kilogram, and / or about 4,700 mg magnesium per kilogram, and / or about 65 mg iron per kilogram, about 6.6 mg zinc per kilogram, and / or about 786 μg selenium per kilogram, and / or about 1,300 μg chromium per kilogram. The sugar cane-derived extract may be in the form of a syrup.
[0234] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 50-350 mg potassium per kilogram, and / or about 5-70 mg sodium per kilogram, and / or about 7,000-10,000 mg calcium per kilogram, and / or about 1,000-3,000 mg magnesium per kilogram, and / or about 500-1,300 mg iron per kilogram. The sugar cane-derived extract may be in powder form.
[0235] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 100-250 mg potassium per kilogram, and / or about 10-50 mg sodium per kilogram, and / or about 8,000-9,000 mg calcium per kilogram, and / or about 1,500-2,500 mg magnesium per kilogram, and / or about 800-1,000 mg iron per kilogram. The sugar cane-derived extract may be in powder form.
[0236] In one embodiment, the sugar cane-derived extract of the present disclosure includes about 190 mg potassium per kilogram, and / or about 30 mg sodium per kilogram, and / or about 8,800 mg calcium per kilogram, and / or about 2,000 mg magnesium per kilogram, and / or about 890 mg iron per kilogram. The sugar cane-derived extract may be in powder form.
[0237] The extract derived from sugar cane of the present disclosure may contain monosaccharides, disaccharides, oligosaccharides and / or polysaccharides. Examples of these include, but are not limited to, sucrose, glucose, galactose, xylose, ribose, mannose, rhamnose, fructose, maltose, lactose, maltotriose, xylopyranose, raffinose, 1-kestose, theanderose, 6-kestose, panose, neose, nesose, glucan and xylan.
[0238] The extract derived from sugar cane of the present disclosure may contain fiber. Fiber may be present in the extract obtained by the process flow, or fiber may be added to the extract. The term "fiber" as used herein refers to the indigestible part of a food derived from a plant. Fiber may be soluble fiber or insoluble fiber. Non-limiting examples of fiber include sugar cane fiber, oat bran, flour (including, for example, soy, rice, wheat, bran, rye, corn, sorghum, potato), modified starch, gelatin, non-starch polysaccharides such as arabinoxylan, cellulose, chia fiber, psyllium fiber, fenugreek fiber, and many other plant components such as resistant starch, resistant dextrin, inulin, lignin, chitin, pectin, beta-glucan and oligosaccharides. In one embodiment, the extract derived from sugar cane of the present disclosure contains sugar cane fiber. In one embodiment, the extract derived from sugar cane of the present disclosure contains flour. In one embodiment, the extract derived from sugar cane of the present disclosure contains modified starch. In one embodiment, the extract derived from sugar cane of the present disclosure contains cellulose. In one embodiment, the sugar cane-derived extract of the present disclosure comprises chia fiber. In one embodiment, the sugar cane-derived extract of the present disclosure comprises psyllium fiber. In one embodiment, the sugar cane-derived extract of the present disclosure comprises fenugreek fiber.
[0239] In one embodiment, fiber is present in the extract of the present disclosure. In one embodiment, fiber is added to the extract of the present disclosure.
[0240] The extract derived from sugar cane of the present disclosure may be in the form of a paste, a crumb, a pellet, a syrup, a liquid, or a powder. In one embodiment, the extract may be in the form of a paste, a crumb, or a pellet. In one embodiment, the extract may be in the form of a paste. In one embodiment, the extract may be in the form of a crumb. In one embodiment, the extract may be in the form of a pellet. In one embodiment, the extract may be in the form of a liquid. In one embodiment, the extract may be in the form of a syrup.
[0241] The extract derived from sugar cane of the present disclosure may be in powder form. In one embodiment, the powder form is a freeze-dried powder form, or a dehydrated powder form or a spray-dried powder form. The extract derived from sugar cane of the present disclosure may be in capsule form.
[0242] It may be desirable to avoid extreme pHs for the sugar cane-derived extracts of the present disclosure. In one embodiment, the pH of the sugar cane-derived extracts of the present disclosure ranges from about 3 to about 7, or from about 3 to about 6, or from about 4 to about 5.5, or from about 4.5 to about 5, or from about 4.6 to about 4.8.
[0243] The Brix values of the extracts derived from sugar cane of the present disclosure may vary. In some cases, the Bx value of the extract is at least about 40°Bx (Brix). In some cases, the Bx value of the extract is at least about 50°Bx. In some cases, the Bx value of the extract is at least about 60°Bx. In some cases, the Bx value of the extract is at least about 65°Bx. In some cases, the Bx value of the extract is at least about 70°Bx. In some cases, the Bx value of the extract is about 50-75°Bx. In some cases, the Bx value of the extract is about 50-70°Bx. In some cases, the Bx value of the extract is about 60-65°Bx. In some cases, the Bx value of the extract is about 50-60°Bx. In some cases, the Bx value of the extract is about 55°Bx. In some cases, the Bx value of the extract is about 60-65°Bx. In some cases, the Bx value of the extract is about 64-65°Bx. In some cases, the Bx value of the extract is about 65-70°Bx. In some cases, the extract has a Bx value of about 70-75° Bx. In some cases, the extract has a Bx value of about 75-80° Bx.
[0244] Compositions, methods and uses of extracts derived from sugar cane
[0245] Composition, animal feed supplement and animal feed
[0246] The sugar cane-derived extracts of the present disclosure may be included in a veterinary composition for administration to an animal, or in an animal supplement or animal feed intended for ingestion by an animal. The veterinary composition, animal supplement or animal feed may be employed in a variety of uses and methods.
[0247] The extract derived from sugar cane of the present disclosure can be prepared into veterinary compositions and unit dosage forms thereof together with conventional adjuvants, carriers or diluents, and in such forms can be used as solids (such as tablets, powders or filled capsules), liquids (such as solutions, suspensions), emulsions (including microemulsions), syrups, elixirs or capsules filled with elixirs, creams, slurries, gels and oils. The extract derived from sugar cane of the present disclosure can be prepared into animal feed supplements or animal feed together with other conventional additives.
[0248] The veterinary composition of the present disclosure may also include other ingredients. For example, but not limited to, the composition of the present disclosure may also include the components listed below. Adhesives such as gum, gum arabic, corn starch or gelatin, excipients such as calcium hydrogen phosphate, disintegrants such as corn starch, potato starch, alginic acid, lubricants such as magnesium stearate, sweeteners such as sucrose, lactose or saccharin, and liquid carriers may be added. Various other ingredients may exist as coatings, or may exist to modify the physical form of the veterinary composition. The veterinary composition may include methylparaben and propylparaben as preservatives, dyes, and flavorings such as cherry or orange flavors. Guidance on additives and excipients suitable for veterinary applications may be found in, for example, Merck Veterinary Manual (Merck Veterinary Manual) (online access to www.merckvetmanual.com).
[0249] Veterinary compositions of the present disclosure can be formulated for oral administration (including buccal or sublingual) or nasal administration (including buccal or sublingual). Therefore, the veterinary compositions of the present invention can be formulated into, for example, tablets, capsules, powders, granules, lozenges, creams or liquid preparations (such as oral solutions or suspensions). Such preparations can be prepared by any method known in the art, for example, by combining an acceptable excipient with an active ingredient or a combination of active ingredients. These preparations can be prepared into enteric-coated granules, tablets or capsules suitable for oral administration, and delayed release preparations. The combination of active ingredients is recommended for liquid delivery and in solids for mixing by animal feed.
[0250] The veterinary compositions of the present disclosure may be in single unit form or in bulk form and may be prepared by any method well known in the art. All methods include the step of combining the extract derived from sugar cane of the present disclosure with one or more adjuvants. Typically, the composition is prepared by uniformly and intimately combining the extract derived from sugar cane of the present disclosure with a liquid carrier or a finely divided solid carrier or both, and then (if necessary) shaping the product into the desired formulation. The term "composition" as used herein is intended to encompass a product comprising the specified ingredients, as well as any product resulting directly or indirectly from a combination of the specified ingredients.
[0251] Veterinary compositions include those for oral administration. Compositions include solutions, syrups, powders, tablets and capsules. In one embodiment, the composition is in dry form or liquid form. In one embodiment, the composition is in dry form. In one embodiment, the composition is in liquid form. In one embodiment, the composition is in syrup form. In one embodiment, the composition is in tablet or capsule form. In one embodiment, the composition is in tablet form. In one embodiment, the composition is in capsule form. These forms are conveniently stable under the conditions of manufacture and storage, and are generally preserved to resist the contaminating effects of microorganisms such as bacteria and fungi.
[0252] The extract derived from sugar cane of the present disclosure can be included in an animal supplement or animal feed intended for ingestion by an animal. The animal supplement and animal feed of the present disclosure can be formulated according to methods well known in the art. Guidance on feed formulation is provided by, for example, the Food and Agriculture Organization of the United Nations (at www.fao.org). It should be recognized that the formulation of the feed depends on the animal subject. For example, animal feeds for monogastric animals such as pigs typically include concentrates and supplements, while animal feeds for ruminants typically include forage (including roughage and silage) and may further include concentrates and supplements. It should also be recognized that feed formulations depend on the availability, quality and cost of ingredients, which may vary with season and geographic location. For example, fish meal has high-quality protein that can meet the requirements of essential amino acids (EAA) in fish feed, but is expensive. Alternatively, a plant protein source (such as soybean meal) or a combination of fish meal and plant protein can be used.
[0253] Supplements may include vitamins, minerals (e.g., calcium, phosphorus, trace elements such as zinc, selenium and chromium, sodium), enzymes (e.g., phytase to improve nutrient digestibility), essential oils, direct-fed microorganisms (to maintain a balanced and healthy gastrointestinal microbiota), organic acids, amino acids (e.g., methionine, lysine and threonine), which may be provided in a premix.
[0254] Other additives include auxiliary components and excipients as described above for veterinary compositions, including: binders, antioxidants, preservatives, colorants, pigments and dyes, flavoring agents (such as sweeteners, which can be used to mask the bitter taste of feed ingredients to improve feed palatability), vehicles, diluents, emulsifiers and suspending agents, attractants, and drugs (including growth promoters, immunostimulants, hormones and antimicrobial agents). In addition, excipients are selected for their suitability in preparing feed forms (e.g., pastes, granules, crumbs, pellets, powders and lick blocks). For example, corn starch or polyvinyl pyrrolidone (PVP) are suitable for forming granular feed products. Guidance on animal feed additives, excipients and supplements is also available from the Food and Agriculture Organization of the United Nations (at www.fao.org) and other sources, for example, in the Merck Veterinary Manual (available online at www.merckvetmanual.com) and the CRC Handbook of Food, Drug and Cosmetic Excipients, 2005.
[0255] The animal supplement or animal feed of the present disclosure may have a Brix value of at least about 40°Bx. In some cases, the Bx value of the animal supplement or animal feed is at least about 50°Bx. In some cases, the Bx value of the animal supplement or animal feed is at least about 60°Bx. In some cases, the Bx value of the animal supplement or animal feed is at least about 65°Bx. In some cases, the Bx value of the animal supplement or animal feed is at least about 70°Bx. In some cases, the Bx value of the animal supplement or animal feed is about 50-75°Bx. In some cases, the Bx value of the animal supplement or animal feed is about 50-70°Bx. In some cases, the Bx value of the animal supplement or animal feed is about 60-65°Bx. In some cases, the Bx value of the animal supplement or animal feed is about 50-60°Bx. In some cases, the Bx value of the animal supplement or animal feed is about 55°Bx. In some cases, the Bx value of the animal supplement or animal feed is about 60-65°Bx. In some cases, the Bx value of the animal supplement or animal feed is about 64-65° Bx. In some cases, the Bx value of the animal supplement or animal feed is about 65-70° Bx. In some cases, the Bx value of the animal supplement or animal feed is about 70-75° Bx. In some cases, the Bx value of the animal supplement or animal feed is about 75-80° Bx.
[0256] The animal supplement or animal feed of the present disclosure may contain fiber. The term "fiber" as used herein refers to the indigestible portion of a food derived from a plant. Fiber may be soluble or insoluble fiber. Fiber may be mixed with an extract of the present disclosure to provide an animal supplement or feed, or fiber may be coated on an extract of the present disclosure to provide an animal supplement or feed. In one embodiment, fiber is mixed with an extract of the present disclosure to provide an animal supplement or feed. In one embodiment, fiber is coated on an extract of the present disclosure to provide an animal supplement or feed.
[0257] Fiber can be present in an animal supplement or animal feed of the present disclosure in an amount of up to about 20wt%. In one embodiment, fiber is present in an animal supplement or animal feed in an amount of up to about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20wt%. In one embodiment, fiber is present in an animal supplement or animal feed in an amount of up to about 0.5wt%. In one embodiment, fiber is present in an animal supplement or animal feed in an amount of up to about 1wt%. In one embodiment, fiber is present in an animal supplement or animal feed in an amount of up to about 1.5wt%. In one embodiment, fiber is present in an animal supplement or animal feed in an amount of up to about 2wt%. In one embodiment, fiber is present in an animal supplement or animal feed in an amount of up to about 3wt%. In one embodiment, the fiber is present in the animal supplement or animal feed in an amount up to about 4 wt%. In one embodiment, the fiber is present in the animal supplement or animal feed in an amount up to about 5 wt%.
[0258] In one embodiment, the fiber is present in an animal supplement or animal feed in an amount up to about 10 wt %. In one embodiment, the fiber is present in an animal supplement or animal feed in an amount up to about 15 wt %. In one embodiment, the fiber is present in an animal supplement or animal feed in an amount up to about 20 wt %.
[0259] Non-limiting examples of fiber include sugar cane fiber, oat bran, flour, modified starch, gelatin, non-starch polysaccharides such as arabinoxylan, cellulose, chia fiber, psyllium fiber, fenugreek fiber, and many other plant components such as resistant starch, resistant dextrin, inulin, lignin, chitin, pectin, beta-glucan and oligosaccharides. In one embodiment, the animal supplement or animal feed of the present disclosure comprises sugar cane fiber. In one embodiment, the animal supplement or animal feed of the present disclosure comprises modified starch. In one embodiment, the animal supplement or animal feed of the present disclosure comprises cellulose. In one embodiment, the animal supplement or animal feed of the present disclosure comprises chia fiber. In one embodiment, the animal supplement or animal feed of the present disclosure comprises psyllium fiber. In one embodiment, the animal supplement or animal feed of the present disclosure comprises fenugreek fiber.
[0260] The compositions, animal supplements or animal feeds of the present disclosure may also contain other compounds that can be used to improve or maintain the health of the animal. According to conventional veterinary principles, those of ordinary skill in the art can select suitable active compounds for combined therapy. The combination of active compounds can act synergistically to achieve improvement or maintenance of animal health. Using this method, efficacy can be achieved with lower doses of various active compounds, thereby reducing potential adverse side effects.
[0261] In one embodiment, the active compound used in the combination therapy is one or more plant bioactive agents. In one embodiment, the active compound used in the combination therapy is one or more marine bioactive substances.
[0262] The composition, animal supplement, or animal feed of the present disclosure may include an extract derived from sugar cane of the present disclosure present in an amount up to about 5.0 wt % based on the total weight of the composition, animal supplement, or animal feed. In one embodiment, the composition, animal supplement, or animal feed of the present disclosure includes an extract derived from sugar cane of the present disclosure present in an amount of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.10, 4.20, 4.30, 4.40, 4.50, 4.6, 4.7, 4.8, 4.9, 5.11, 5.2 .5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 15.0 or 20.0 wt % of the extract derived from sugar cane of the present disclosure. In one embodiment, the composition, animal supplement or animal feed of the present disclosure comprises the extract derived from sugar cane of the present disclosure present in an amount of 0.1 wt % to 5 wt % based on the total weight of the composition, animal supplement or animal feed. In one embodiment, the composition, animal supplement or animal feed of the present disclosure comprises an extract derived from sugar cane of the present disclosure present in an amount of 0.1 wt% to 0.5 wt% based on the total weight of the composition, animal supplement or animal feed. In one embodiment, the composition, animal supplement or animal feed of the present disclosure comprises an extract derived from sugar cane of the present disclosure present in an amount of 0.1 wt% to 1 wt% based on the total weight of the composition, animal supplement or animal feed. In one embodiment, the composition, animal supplement or animal feed of the present disclosure comprises an extract derived from sugar cane of the present disclosure present in an amount of 0.1 wt% to 2 wt% based on the total weight of the composition, animal supplement or animal feed. In one embodiment, the composition, animal supplement or animal feed of the present disclosure comprises an extract derived from sugar cane of the present disclosure present in an amount of 0.01 wt% to 1 wt% based on the total weight of the composition, animal supplement or animal feed. In one embodiment, the composition, animal supplement, or animal feed of the present disclosure comprises an extract derived from sugar cane of the present disclosure present in an amount of 0.01 wt% to 0.05 wt% based on the total weight of the composition, animal supplement, or animal feed. In one embodiment, the composition, animal supplement, or animal feed of the present disclosure comprises an extract derived from sugar cane of the present disclosure present in an amount of 0.01 wt% to 2 wt% based on the total weight of the composition, animal supplement, or animal feed.
[0263] In one aspect of the present disclosure, an animal feed is provided, comprising an animal supplement as described herein. In one embodiment, the supplement is present in an amount of up to about 20wt% in the animal feed. In one embodiment, the supplement is present in an amount of up to about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20wt% in the animal feed. In one embodiment, the supplement is present in an amount of up to about 0.5wt% in the animal feed. In one embodiment, the supplement is present in an amount of up to about 1wt% in the animal feed. In one embodiment, the supplement is present in an amount of up to about 2wt% in the animal feed. In one embodiment, the supplement is present in an amount of up to about 5wt% in the animal feed. In one embodiment, the supplement is present in an amount of up to about 10wt% in the animal feed. In one embodiment, the supplement is present in the animal feed in an amount up to about 15 wt%. In one embodiment, the supplement is present in the animal feed in an amount up to about 20 wt%.
[0264] In one aspect of the present disclosure, a non-human animal formula supplement is provided that includes an extract derived from sugar cane. In one embodiment, the extract includes about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0265] In one embodiment, the extract comprises at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 CE g / L of polyphenols. In one embodiment, the extract comprises at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 250, 275, 300, 325, 350, 375, 400, 425, 450, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, or 800 mg CE / g of polyphenols.
[0266] In one embodiment, the extract comprises about 1 CE g / L to about 50 CE g / L of polyphenols or about 10 CE mg / g to about 500 CE mg / g of polyphenols. In one embodiment, the extract comprises about 1 CE g / L to about 25 CE g / L of polyphenols or about 10 CE mg / g to about 250 CE mg / g of polyphenols. In one embodiment, the extract comprises about 1 CE g / L to about 10 CE g / L of polyphenols or about 10 CE mg / g to about 100 CE mg / g of polyphenols. In one embodiment, the extract comprises about 1 CE g / L to about 5 CE g / L of polyphenols or about 10 CE mg / g to about 50 CE mg / g of polyphenols.
[0267] In one embodiment, the extract comprises about 5CE g / L to about 50CE g / L of polyphenols or about 50CE mg / g to about 500CE mg / g of polyphenols. In one embodiment, the extract comprises about 5CE g / L to about 25CE g / L of polyphenols or about 50CE mg / g to about 250CE mg / g of polyphenols. In one embodiment, the extract comprises about 5CE g / L to about 10CE g / L of polyphenols or about 50CE mg / g to about 100CE mg / g of polyphenols.
[0268] In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10CE g / L to about 100CE g / L of polyphenols or about 100CE mg / g to about 1000CE mg / g of polyphenols. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10CE g / L to about 90CE g / L of polyphenols or about 100CE mg / g to about 900CE mg / g of polyphenols. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10CE g / L to about 80CE g / L of polyphenols or about 100CE mg / g to about 800CE mg / g of polyphenols. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10CE g / L to about 70CE g / L of polyphenols or about 100CE mg / g to about 700CE mg / g of polyphenols. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10 CE g / L to about 60 CE g / L of polyphenols or about 100 CE mg / g to about 600 CE mg / g of polyphenols. In one embodiment, the extract comprises about 10 CE g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols. In one embodiment, the extract comprises about 10 CE g / L to about 25 CE g / L of polyphenols or about 100 CE mg / g to about 250 CE mg / g of polyphenols.
[0269] In one embodiment, the extract comprises about 15 CE g / L to about 50 CE g / L of polyphenols or about 150 CE mg / g to about 500 CE mg / g of polyphenols. In one embodiment, the extract comprises about 15 CE g / L to about 25 CE g / L of polyphenols or about 150 CE mg / g to about 250 CE mg / g of polyphenols.
[0270] In one embodiment, the extract comprises about 10 CE g / L to about 70 CE g / L of polyphenols or about 100 CE mg / g to about 700 CE mg / g of polyphenols. In one embodiment, the extract comprises about 10 CE g / L to about 60 CE g / L of polyphenols or about 100 CE mg / g to about 600 CE mg / g of polyphenols. In one embodiment, the extract comprises about 10 CE g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0271] In one embodiment, the extract comprises about 15CE g / L to about 40CE g / L of polyphenols or about 150CE mg / g to about 400CE mg / g of polyphenols. In one embodiment, the extract comprises about 20CE g / L to about 30CE g / L of polyphenols or about 200CE mg / g to about 300CE mg / g of polyphenols. In one embodiment, the extract comprises about 20CE g / L to about 27g CE / L of polyphenols or about 200CE mg / g to about 270CE mg / g of polyphenols. In one embodiment, the extract comprises about 27CE g / L to about 35g CE / L of polyphenols or about 270CE mg / g to about 350CE mg / g of polyphenols. In one embodiment, the extract comprises about 35CE g / L to about 40g CE / L of polyphenols or about 350CE mg / g to about 400CE mg / g of polyphenols. In one embodiment, the extract comprises about 40CE g / L to about 50gCE / L of polyphenols or about 400CE mg / g to about 500CE mg / g of polyphenols. In one embodiment, the extract comprises about 45 CE g / L to about 50 g CE / L of polyphenols or about 450 CE mg / g to about 500 CE mg / g of polyphenols.
[0272] Methods and uses
[0273] The sugar cane-derived extracts of the present disclosure include a complex mixture of plant primary metabolites and plant secondary metabolites, including polyphenols. The collective diversity and quantity of plant primary metabolites and plant secondary metabolites, including polyphenols, in the extracts greatly exceed typical levels in a normal animal diet. When the extracts are consumed by animal subjects, the plant metabolites stimulate a variety of biological mechanisms in the animals, including, for example, antioxidant pathways, anti-inflammatory pathways, and immunomodulatory pathways, resulting in a number of beneficial health effects. The results described in the present disclosure demonstrate the current understanding of the effects of the extracts on a variety of biological mechanisms and the resulting health effects. However, due to the complex nature of the extracts and the current state of the art, other biological mechanisms may exist but have not yet been described.
[0274] Compositions, supplements and feeds comprising extracts of the present disclosure can be used to improve or maintain the health of animal subjects. The inventors of the present application surprisingly found that the extracts derived from sugar cane of the present disclosure have properties that make them suitable for use in improving or maintaining the health of animals. Representative properties include: beneficial immunomodulatory effects, in which local or systemic immune responses are beneficially stimulated or modulated; anti-inflammatory effects; antioxidant effects; cytoprotective effects; and antimicrobial effects, in which gastrointestinal microbiota function is improved or maintained. Other beneficial properties include antiviral activity; antibacterial activity; anticancer activity; cardiovascular benefits; antiulcer activity; vasodilatory properties; gene regulatory properties; anti-caries and analgesic properties.
[0275] In one embodiment, compositions, supplements and feeds comprising extracts of the present disclosure improve or maintain the health of non-human animals. In one embodiment, compositions, supplements and feeds comprising extracts of the present disclosure have beneficial immunomodulatory effects. In one embodiment, compositions, supplements and feeds comprising extracts of the present disclosure have anti-inflammatory effects. In one embodiment, compositions, supplements and feeds comprising extracts of the present disclosure have antioxidant effects. In one embodiment, compositions, supplements and feeds comprising extracts of the present disclosure have cytoprotective effects. In one embodiment, compositions, supplements and feeds comprising extracts of the present disclosure have antimicrobial effects. In one embodiment, compositions, supplements and feeds comprising extracts of the present disclosure improve or maintain gastrointestinal microbial population function. In one embodiment, compositions, supplements and feeds comprising extracts of the present disclosure have anti-ulcer activity.
[0276] In one aspect of the present disclosure, a method for improving or maintaining gastrointestinal health of a non-human animal subject is provided, the method comprising the step of administering an effective amount of a supplement or feed as described herein. In one embodiment, gastrointestinal microbiota function is improved or maintained.
[0277] In one aspect of the present disclosure, a method for improving growth performance of a non-human animal subject is provided, the method comprising the step of administering an effective amount of a supplement or animal feed as described herein. In one embodiment, the size of the subject increases. In one embodiment, the weight gain of the subject increases. In one embodiment, the average weight gain of the subject increases. In one embodiment, the daily weight gain of the subject increases. In one embodiment, the average daily weight gain of the subject increases. In one embodiment, the weight gain is a live weight gain. In one embodiment, the length of the subject increases. In one embodiment, the standard length of the subject increases. In one embodiment, the average standard length of the subject increases. In one embodiment, the fork length of the subject increases, wherein the subject is a finfish. In one embodiment, the average fork length of the subject increases, wherein the subject is a finfish. In one embodiment, the total length of the subject increases. In one embodiment, the average total length of the subject increases. In one embodiment, the body length of the subject increases. In one embodiment, the average body length of the subject increases. In one embodiment, the head length of the subject increases. In one embodiment, the average head length of the subject increases. In one embodiment, the feed conversion ratio (FCR) is reduced.
[0278] In one aspect of the present disclosure, a method for reducing body fat content in a non-human animal subject is provided, the method comprising the step of administering an effective amount of a supplement or feed as described herein. In one embodiment, the subject's body weight is subsequently reduced. In one embodiment, peripheral and / or visceral fat is reduced.
[0279] In one embodiment, there is no adverse effect on blood health. In one embodiment, there is no adverse effect on blood health as assessed by complete blood count (CBC) analysis. In one embodiment, there is no adverse effect on blood health as assessed by counting the number of red blood cells (RBC) and / or the number of white blood cells (WBC). In one embodiment, there is no adverse effect on blood health as assessed by analysis of total hemoglobin in the blood. In one embodiment, there is no adverse effect on blood health as assessed by analysis of the portion of the blood consisting of RBCs (hematocrit).
[0280] In one embodiment, there is no adverse effect on urinary health. In one embodiment, there is no adverse effect on urine pH. In one embodiment, there is no adverse effect on urine specific gravity.
[0281] In one aspect of the present disclosure, a method for improving nutrient digestibility in a non-human animal subject is provided, the method comprising the step of administering to the subject an effective amount of a supplement or animal feed as described herein. In one embodiment, the digestible food remaining in the feces of the subject is negligible.
[0282] In one aspect of the present disclosure, a method for reducing feed conversion ratio (FCR) in a non-human animal subject is provided, the method comprising administering to the subject an effective amount of a supplement or feed described herein.
[0283] In one aspect of the present disclosure, methods for improving food production and quality are provided. In one embodiment, milk production is improved. In one aspect of the present disclosure, methods for improving the quality of meat of a non-human animal subject are provided, the method comprising administering to the subject an effective amount of a supplement or feed as described herein. In one embodiment, the toughness of the meat is improved. In one embodiment, the toughness of the meat is improved as assessed by shear force measurement. In one embodiment, the taste of the meat is improved. In one embodiment, the flavor of the meat is improved. In one embodiment, the odor of the meat is reduced. In one embodiment, the percentage of protein in the meat is increased. In one embodiment, the shelf life of the meat is extended. As will be understood by those skilled in the art, the shelf life is the recommended maximum time that a product or fresh (harvested) product can be stored during which a defined quality of a specified proportion of the goods remains acceptable under the expected (or specified) conditions of distribution, storage and display. In one embodiment, the rancidity of the meat is delayed or slowed. As will be understood by those skilled in the art, rancidity is a process that causes a substance to become rancid, i.e., to have an unpleasant, unpleasant odor or taste. Specifically, this is the hydrolysis and / or autoxidation of fats into short-chain aldehydes and ketones, which are objectionable in taste and odor.
[0284] In one aspect of the present disclosure, a method for preventing and / or treating anemia in a non-human animal subject is provided, wherein the method comprises the step of administering an effective amount of a supplement or feed as described herein. In one embodiment, the anemia is vitamin deficiency anemia. In one embodiment, the anemia is iron deficiency anemia. In one embodiment, the extract further comprises iron bound to the polyphenols.
[0285] In the method for preventing and / or treating anemia in non-human animal subjects, the frequency and amount of the non-human animal formula supplement or non-human animal feed administered can be varied as needed to prevent and / or treat anemia in animal subjects. In one embodiment, the dosage is in the range of about 100 mg to 300 mg at birth, and then in the range of about 100 mg to 300 mg at 14 days. In one embodiment, the dosage is in the range of about 150 mg to 250 mg at birth, and then in the range of about 150 mg to 250 mg at 14 days. In one embodiment, the dosage is in the range of about 100 mg to 200 mg at birth, and then in the range of about 100 mg to 200 mg at 14 days. In one embodiment, the dosage is about 300 mg at birth, and then about 300 mg at 14 days. In one embodiment, the dosage is about 300 mg at birth, and then about 300 mg at 14 days. In one embodiment, the supplement is administered at birth at a fixed dose of about 250 mg, followed by a fixed dose of about 250 mg at 14 days. In one embodiment, the supplement is administered at birth at a fixed dose of about 200 mg, followed by a fixed dose of about 200 mg at 14 days. In one embodiment, the supplement is administered at birth at a fixed dose of about 150 mg, followed by a fixed dose of about 150 mg at 14 days.
[0286] In one embodiment, the subject is a pig. In one embodiment, the white blood cell count in a blood sample drawn from a pig subject is increased. In one embodiment, the red blood cell count in a blood sample drawn from a pig subject is increased. In one embodiment, the hemoglobin concentration in a blood sample drawn from a pig subject is increased. In one embodiment, the growth performance of a pig subject is improved. In one embodiment, the weight gain of a pig is increased. In one embodiment, the weight gain is in vivo weight gain.
[0287] In one aspect of the present disclosure, a method for improving or maintaining muscle condition in a non-human animal subject is provided, wherein the method comprises the step of administering an effective amount of a supplement or feed as described herein. In one embodiment, muscle structure is improved. In one embodiment, muscle shape is improved.
[0288] In one aspect of the present disclosure, a method for stimulating or maintaining appetite in a non-human animal subject is provided, wherein the method comprises the step of administering an effective amount of a supplement or feed described herein.
[0289] In one aspect of the present disclosure, a method of preventing, reducing and / or treating gastric ulcers in a non-human animal subject is provided, the method comprising the step of administering an effective amount of a non-human animal formula supplement or a non-human animal feed as described herein. In one embodiment, gastric ulcers are prevented. In one embodiment, ulcers are treated. In one embodiment, gastric ulcers are reduced. In one embodiment, the animal subject is a horse.
[0290] Compositions, non-human animal formula supplements and non-human animal feeds comprising the extracts of the present disclosure can be administered or fed to non-human animal subjects. The term "animal subject" as used herein refers to any animal other than humans. Therefore, the present disclosure relates to non-human animals. The non-human animal can be a mammal. Examples of non-human animals include aquatic animals, insects, amphibians, reptiles, gastropods, birds, monogastric animals, ruminants and pseudo-ruminants.
[0291] In one embodiment, the animal is an aquatic animal. In one embodiment, the aquatic animal is finfish and shellfish. In one embodiment, the aquatic animal is finfish. In one embodiment, the aquatic animal is shellfish. In one embodiment, the finfish is pangasius. In one embodiment, the finfish is tilapia. In one embodiment, the finfish is salmon. In one embodiment, the finfish is barramundi. In one embodiment, the finfish is selected from the group consisting of barramundi, bass, bream, carp, catfish, cod, crappie, drum, eel, goby, goldfish, grouper, halibut, Java fish, rohu, wrasse, loach, mackerel, milkfish, silver perch, mudfish, mullet, paco, pearl spot, silverside, perch, pike, pompano, carp, salmon, long-finned catfish, Canadian zander, sea bass, sea bream, shiner, sleeper, snakehead, snapper, cobia, sole, lancefoot, sturgeon, sunfish, sweetfish, tench, crown fish, trout, tuna, turbot, whitefish, walleye, and whitefish.
[0292] In one embodiment, the aquatic animal is a shellfish. In one embodiment, the shellfish is a crustacean. In one embodiment, the shellfish is a mollusk. In one embodiment, the shellfish is a crustacean selected from the group consisting of crabs, crayfish, lobsters, prawns, and shrimps. In one embodiment, the shellfish is a prawn. In one embodiment, the shellfish is a shrimp. In one embodiment, the shellfish is a mollusk selected from the group consisting of clams, mussels, oysters, scallops, and litmus. In one embodiment, the shellfish is a mussel. In one embodiment, the shellfish is an oyster. In one embodiment, the shellfish is a scallop.
[0293] In one embodiment, the animal is an insect. In one embodiment, the insect is selected from the group consisting of cicadas, grasshoppers, beetles, bees, wasps, butterflies, moths, ants, flies, crickets, aphids, bedbugs, and dragonflies. In one embodiment, the insect is a grasshopper. In one embodiment, the insect is a bee. In one embodiment, the insect is a cricket. In one embodiment, the insect is a butterfly.
[0294] In one embodiment, the animal is an amphibian. In one embodiment, the amphibian is selected from the group consisting of a frog, a toad, and a salamander. In one embodiment, the amphibian is a frog. In one embodiment, the amphibian is a toad. In one embodiment, the amphibian is a salamander.
[0295] In one embodiment, the animal is a reptile. In one embodiment, the reptile is selected from the group consisting of snakes, lizards, iguanas, turtles, and crocodiles. In one embodiment, the reptile is a snake. In one embodiment, the reptile is a lizard. In one embodiment, the reptile is a turtle. In one embodiment, the reptile is a crocodile.
[0296] In one embodiment, the animal is a bird. In one embodiment, the bird is selected from poultry such as chicken, duck, goose, turkey, quail, guinea fowl, pigeon (including chicks) and raptors (including eagles, eagles, kites, falcons, vultures, harriers, ospreys and owls). In one embodiment, the bird is selected from chicken, duck, goose and turkey. In one embodiment, the bird is poultry. In one embodiment, the bird is a chicken. In one embodiment, the bird is a broiler. In one embodiment, the bird is an egg-laying hen. In one embodiment, the bird is a duck. In one embodiment, the bird is a goose. In one embodiment, the bird is a turkey. In one embodiment, the bird is a quail. In one embodiment, the bird is a guinea fowl. In one embodiment, the bird is a pigeon. In one embodiment, the bird is a raptor.
[0297] In one embodiment, the animal is a monogastric animal. In one embodiment, the monogastric animal is selected from pigs or swine (e.g., piglets, growing pigs, and sows), cats and dogs, rodents (rats, mice). In one embodiment, the monogastric animal is a pig. In one embodiment, the monogastric animal is a cat. In one embodiment, the monogastric animal is a dog. In one embodiment, the monogastric animal is a rodent. In one embodiment, the monogastric animal is a mouse. In one embodiment, the monogastric animal is a rat.
[0298] In one embodiment, the animal is a ruminant. In one embodiment, the animal is a ruminant selected from cattle, sheep, goats, deer, yaks, camels, llamas and kangaroos. Cattle include but are not limited to beef cattle, dairy cows, cows and calves. In one embodiment, the ruminant is selected from cattle, sheep, goats and deer. In one embodiment, the ruminant is a cow. In one embodiment, the ruminant is a beef cattle. In one embodiment, the ruminant is a dairy cow. In one embodiment, the ruminant is a calf. In one embodiment, the ruminant is a sheep. In one embodiment, the ruminant is a goat. In one embodiment, the ruminant is a deer. In one embodiment, the ruminant is a llama. In one embodiment, the ruminant is a kangaroo.
[0299] In one embodiment, the animal is a pseudo-ruminant. In one embodiment, the pseudo-ruminant is selected from the group consisting of horses, camels, rabbits, and guinea pigs. In one embodiment, the pseudo-ruminant is selected from the group consisting of horses, rabbits, and guinea pigs. In one embodiment, the pseudo-ruminant is a horse. In one embodiment, the pseudo-ruminant is a rabbit. In one embodiment, the pseudo-ruminant is a camel. In one embodiment, the pseudo-ruminant is a guinea pig.
[0300] In the methods of the present disclosure, administration may be by oral administration.
[0301] The frequency of administration of the extract derived from sugar cane or a composition comprising an extract derived from sugar cane, a non-human animal formula supplement or an animal feed can be the frequency of administration required to provide the desired improvement, maintenance, prevention and / or treatment. As will be appreciated by one of ordinary skill in the art, the frequency of administration of the extract derived from sugar cane or a composition comprising an extract derived from sugar cane, a non-human animal formula supplement or an animal feed can depend on the amount or dose of the extract. A higher amount or a higher dose of the extract derived from sugar cane may result in a reduced frequency of administration required. A lower amount or a lower dose of the sugar cane extract may result in a more frequent administration required. Administration of the extract derived from sugar cane or a composition comprising an extract derived from sugar cane, a non-human animal formula supplement or an animal feed can be short-term, long-term or continuous.
[0302] The frequency of administration can be daily, twice daily, three times daily, every 1-3 days, every 1-5 days, weekly, every two weeks, monthly, every two months, every 1-3 months, every 1-6 months, every 6 months, or annually. In one embodiment, the frequency of administration is daily. In one embodiment, the frequency of administration is twice daily. In one embodiment, the frequency of administration is weekly. In one embodiment, the frequency of administration is every two weeks. In one embodiment, the frequency of administration is monthly. In one embodiment, the frequency of administration is every two months. In one embodiment, the frequency of administration is every 1-3 months. In one embodiment, the frequency of administration is every 1-6 months. In one embodiment, the frequency of administration is every 6 months. In one embodiment, the frequency of administration is annually.
[0303] However, it should be understood that the specific dosage level and dosage frequency for any particular subject may vary and will depend on a variety of factors including the activity of the specific extract derived from sugar cane used, the activity of the veterinary composition, non-human animal formulation supplement or animal feed comprising the extract, the metabolic stability and duration of action of the sugar cane derived extract, veterinary composition, non-human animal formulation supplement or animal feed, age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, severity of the particular disease, and the animal subject being treated.
[0304] The compositions, non-human animal formula supplements, non-human animal feeds, methods or uses of the present disclosure may also include other active agents or compounds to improve or maintain the health of the animal. One of ordinary skill in the art can select suitable agents or compounds for combination.
[0305] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for improving or maintaining gastrointestinal health in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0306] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for improving growth performance in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0307] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for reducing body fat content in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0308] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for improving nutrient digestibility in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0309] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for reducing feed conversion ratio (FCR) of a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0310] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for improving meat quality in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0311] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a medicament for preventing and / or treating anemia in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0312] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for improving or maintaining muscle condition in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0313] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement for stimulating or maintaining appetite in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0314] In another aspect of the present disclosure, there is provided a use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0315] With regard to the above uses, in one embodiment, the extract comprises at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 CE g / L of polyphenols. In one embodiment, the extract comprises at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 250, 275, 300, 325, 350, 375, 400, 425, 450, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, or 800 mg CE / g of polyphenols.
[0316] In one embodiment, the extract comprises about 1 CE g / L to about 50 CE g / L of polyphenols or about 10 CE mg / g to about 500 CE mg / g of polyphenols. In one embodiment, the extract comprises about 1 CE g / L to about 25 CE g / L of polyphenols or about 10 CE mg / g to about 250 CE mg / g of polyphenols. In one embodiment, the extract comprises about 1 CE g / L to about 10 CE g / L of polyphenols or about 10 CE mg / g to about 100 CE mg / g of polyphenols. In one embodiment, the extract comprises about 1 CE g / L to about 5 CE g / L of polyphenols or about 10 CE mg / g to about 50 CE mg / g of polyphenols.
[0317] In one embodiment, the extract comprises about 5CE g / L to about 50CE g / L of polyphenols or about 50CE mg / g to about 500CE mg / g of polyphenols. In one embodiment, the extract comprises about 5CE g / L to about 25CE g / L of polyphenols or about 50CE mg / g to about 250CE mg / g of polyphenols. In one embodiment, the extract comprises about 5CE g / L to about 10CE g / L of polyphenols or about 50CE mg / g to about 100CE mg / g of polyphenols.
[0318] In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10CE g / L to about 100CE g / L of polyphenols or about 100CE mg / g to about 1000CE mg / g of polyphenols. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10CE g / L to about 90CE g / L of polyphenols or about 100CE mg / g to about 900CE mg / g of polyphenols. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10CE g / L to about 80CE g / L of polyphenols or about 100CE mg / g to about 800CE mg / g of polyphenols. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10CE g / L to about 70CE g / L of polyphenols or about 100CE mg / g to about 700CE mg / g of polyphenols. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10 CE g / L to about 60 CE g / L of polyphenols or about 100 CE mg / g to about 600 CE mg / g of polyphenols. In one embodiment, the extract comprises about 10 CE g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols. In one embodiment, the extract comprises about 10 CE g / L to about 25 CE g / L of polyphenols or about 100 CE mg / g to about 250 CE mg / g of polyphenols.
[0319] In one embodiment, the extract comprises about 15 CE g / L to about 50 CE g / L of polyphenols or about 150 CE mg / g to about 500 CE mg / g of polyphenols. In one embodiment, the extract comprises about 15 CE g / L to about 25 CE g / L of polyphenols or about 150 CE mg / g to about 250 CE mg / g of polyphenols.
[0320] In one embodiment, the extract comprises about 10 CE g / L to about 70 CE g / L of polyphenols or about 100 CE mg / g to about 700 CE mg / g of polyphenols. In one embodiment, the extract comprises about 10 CE g / L to about 60 CE g / L of polyphenols or about 100 CE mg / g to about 600 CE mg / g of polyphenols. In one embodiment, the extract comprises about 10 CE g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0321] In one embodiment, the extract comprises about 15CE g / L to about 40CE g / L of polyphenols or about 150CE mg / g to about 400CE mg / g of polyphenols. In one embodiment, the extract comprises about 20CE g / L to about 30CE g / L of polyphenols or about 200CE mg / g to about 300CE mg / g of polyphenols. In one embodiment, the extract comprises about 20CE g / L to about 27g CE / L of polyphenols or about 200CE mg / g to about 270CE mg / g of polyphenols. In one embodiment, the extract comprises about 27CE g / L to about 35g CE / L of polyphenols or about 270CE mg / g to about 350CE mg / g of polyphenols. In one embodiment, the extract comprises about 35CE g / L to about 40g CE / L of polyphenols or about 350CE mg / g to about 400CE mg / g of polyphenols. In one embodiment, the extract comprises about 40CE g / L to about 50gCE / L of polyphenols or about 400CE mg / g to about 500CE mg / g of polyphenols. In one embodiment, the extract comprises about 45 CE g / L to about 50 g CE / L of polyphenols or about 450 CE mg / g to about 500 CE mg / g of polyphenols.
[0322] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for use in improving or maintaining gastrointestinal health in a non-human animal subject is provided.
[0323] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for improving growth performance in a non-human animal subject is provided.
[0324] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for use in reducing body fat content in a non-human animal subject is provided.
[0325] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for improving nutrient digestibility in a non-human animal subject is provided.
[0326] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for reducing feed conversion ratio (FCR) in a non-human animal subject is provided.
[0327] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for improving meat quality in a non-human animal subject is provided.
[0328] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for use in preventing and / or treating anemia in a non-human animal subject is provided.
[0329] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for use in preventing and / or treating iron deficiency anemia in a non-human animal subject is provided.
[0330] In another aspect of the present disclosure, a non-human animal formulation supplement as described herein for improving or maintaining muscle condition in a non-human animal subject is provided.
[0331] In another aspect of the present disclosure, a non-human animal formula supplement as described herein for stimulating or maintaining appetite in a non-human animal subject is provided.
[0332] In another aspect of the present disclosure, a non-human animal feed as described herein for use in improving or maintaining gastrointestinal health in a non-human animal subject is provided.
[0333] In another aspect of the present disclosure, a non-human animal feed as described herein for improving growth performance of a non-human animal subject is provided.
[0334] In another aspect of the present disclosure, a non-human animal feed as described herein for reducing body fat content in a non-human animal subject is provided.
[0335] In another aspect of the present disclosure, a non-human animal feed as described herein for improving nutrient digestibility in a non-human animal subject is provided.
[0336] In another aspect of the present disclosure, a non-human animal feed as described herein for reducing the feed conversion ratio (FCR) of a non-human animal subject is provided.
[0337] In another aspect of the present disclosure, a non-human animal feed as described herein for improving meat quality in a non-human animal subject is provided.
[0338] In another aspect of the present disclosure, a non-human animal feed as described herein for use in preventing and / or treating anemia in a non-human animal subject is provided.
[0339] In another aspect of the present disclosure, a non-human animal feed as described herein for use in preventing and / or treating iron deficiency anemia in a non-human animal subject is provided.
[0340] In another aspect of the present disclosure, a non-human animal feed as described herein for improving or maintaining muscle condition in a non-human animal subject is provided.
[0341] In another aspect of the present disclosure, a non-human animal feed as described herein for stimulating or maintaining appetite in a non-human animal subject is provided.
[0342] In another aspect of the present disclosure, a non-human animal formula supplement is provided that includes an extract derived from sugar cane, the extract including about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols, wherein the extract includes iron bound to the polyphenols.
[0343] In another aspect of the present disclosure, a non-human animal feed is provided that includes a non-human animal formula supplement that includes an extract derived from sugar cane, the extract including about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols, wherein the extract includes iron bound to the polyphenols.
[0344] With respect to the above-mentioned non-human animal formula supplements and non-human animal feeds, in one embodiment, the extract includes at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 CE g / L of polyphenols. In one embodiment, the extract comprises at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 250, 275, 300, 325, 350, 375, 400, 425, 450, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, or 800 mg CE / g of polyphenols.
[0345] In one embodiment, the extract comprises about 1 CE g / L to about 50 CE g / L of polyphenols or about 10 CE mg / g to about 500 CE mg / g of polyphenols. In one embodiment, the extract comprises about 1 CE g / L to about 25 CE g / L of polyphenols or about 10 CE mg / g to about 250 CE mg / g of polyphenols. In one embodiment, the extract comprises about 1 CE g / L to about 10 CE g / L of polyphenols or about 10 CE mg / g to about 100 CE mg / g of polyphenols. In one embodiment, the extract comprises about 1 CE g / L to about 5 CE g / L of polyphenols or about 10 CE mg / g to about 50 CE mg / g of polyphenols.
[0346] In one embodiment, the extract comprises about 5CE g / L to about 50CE g / L of polyphenols or about 50CE mg / g to about 500CE mg / g of polyphenols. In one embodiment, the extract comprises about 5CE g / L to about 25CE g / L of polyphenols or about 50CE mg / g to about 250CE mg / g of polyphenols. In one embodiment, the extract comprises about 5CE g / L to about 10CE g / L of polyphenols or about 50CE mg / g to about 100CE mg / g of polyphenols.
[0347] In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10CE g / L to about 100CE g / L of polyphenols or about 100CE mg / g to about 1000CE mg / g of polyphenols. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10CE g / L to about 90CE g / L of polyphenols or about 100CE mg / g to about 900CE mg / g of polyphenols. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10CE g / L to about 80CE g / L of polyphenols or about 100CE mg / g to about 800CE mg / g of polyphenols. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10CE g / L to about 70CE g / L of polyphenols or about 100CE mg / g to about 700CE mg / g of polyphenols. In one embodiment, the extract derived from sugar cane of the present disclosure comprises about 10 CE g / L to about 60 CE g / L of polyphenols or about 100 CE mg / g to about 600 CE mg / g of polyphenols. In one embodiment, the extract comprises about 10 CE g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols. In one embodiment, the extract comprises about 10 CE g / L to about 25 CE g / L of polyphenols or about 100 CE mg / g to about 250 CE mg / g of polyphenols.
[0348] In one embodiment, the extract comprises about 15 CE g / L to about 50 CE g / L of polyphenols or about 150 CE mg / g to about 500 CE mg / g of polyphenols. In one embodiment, the extract comprises about 15 CE g / L to about 25 CE g / L of polyphenols or about 150 CE mg / g to about 250 CE mg / g of polyphenols.
[0349] In one embodiment, the extract comprises about 10 CE g / L to about 70 CE g / L of polyphenols or about 100 CE mg / g to about 700 CE mg / g of polyphenols. In one embodiment, the extract comprises about 10 CE g / L to about 60 CE g / L of polyphenols or about 100 CE mg / g to about 600 CE mg / g of polyphenols. In one embodiment, the extract comprises about 10 CE g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
[0350] In one embodiment, the extract comprises about 15CE g / L to about 40CE g / L of polyphenols or about 150CE mg / g to about 400CE mg / g of polyphenols. In one embodiment, the extract comprises about 20CE g / L to about 30CE g / L of polyphenols or about 200CE mg / g to about 300CE mg / g of polyphenols. In one embodiment, the extract comprises about 20CE g / L to about 27g CE / L of polyphenols or about 200CE mg / g to about 270CE mg / g of polyphenols. In one embodiment, the extract comprises about 27CE g / L to about 35g CE / L of polyphenols or about 270CE mg / g to about 350CE mg / g of polyphenols. In one embodiment, the extract comprises about 35CE g / L to about 40g CE / L of polyphenols or about 350CE mg / g to about 400CE mg / g of polyphenols. In one embodiment, the extract comprises about 40CE g / L to about 50gCE / L of polyphenols or about 400CE mg / g to about 500CE mg / g of polyphenols. In one embodiment, the extract comprises about 45 CE g / L to about 50 g CE / L of polyphenols or about 450 CE mg / g to about 500 CE mg / g of polyphenols.
[0351] Those skilled in the art will appreciate that, without departing from the broad general scope of the present disclosure, various variations and / or modifications may be made to the above-described embodiments. Therefore, the present embodiments should be considered in all aspects as illustrative and not restrictive.
[0352] Example
[0353] Example 1 provides an illustrative and non-limiting example of the characterization of a sugar cane-derived extract of the present disclosure.
[0354] Example 1. Characterization of extracts derived from sugar cane
[0355] To characterize the type and amount of polyphenols in the sugar cane derived extracts according to the present disclosure, some extracts were analyzed by liquid chromatography-mass spectrometry (LCMS) and by nuclear magnetic resonance spectroscopy.
[0356] The three sample extracts A, B and C are fractions of molasses ( Figure 1 ). All samples were stored at -20°C.
[0357] Table 1. Extraction fractions from molasses
[0358] coding Sample name describe A FPX66-bound fraction Brown syrup B FPX66 unbound fraction Light yellow syrup C 74 degrees Brix Dark brown syrup
[0359] 1 mL of each sample was transferred in duplicate to pre-weighed vials and then freeze-dried for 3 days to obtain dry mass (Table 2). One replicate of each sample was analyzed by nuclear magnetic resonance (NMR) spectroscopy, while another replicate of each sample was used for quantitative analysis of polyphenols by LCMS.
[0360] Table 2. Moisture content of samples
[0361]
[0362] The 74 Brix sample was fractionated by C18 solid phase extraction (SPE) to remove sugars and obtain more concentrated phenolic components. 1 mL was diluted in Milli-Q water and eluted through a Waters 3 mL SPE Vac C18 column, which was first activated with MeOH and then adjusted with Milli-Q water. The polar components were eluted with discarded 6 mL Milli-Q water. The remaining metabolites on the SPE column were then eluted into a pre-weighed vial with 2×3 mL MeOH, and the solution was evaporated to dryness under nitrogen. The 74 Brix SPE-MeOH fraction was further dried overnight in a freeze dryer and then weighed to obtain the dry weight of the fraction (55.6 mg). The extract was reconstituted in 200 μL 80:20 MeOH-H2O (concentration = 278 mg / mL) and analyzed on LCMS.
[0363] Reference Standards
[0364] Reference standards used for qualitative analysis of phenolic compounds by LCMS are listed in Table 3. Standard solutions were prepared in MeOH or 1:1 MeOH-H2O. Fourteen standards were used for quantitative analysis of phenolic compounds by LCMS, and a range of concentrations were prepared from the stock solutions shown in Table 3 using 80:20 MeOH-H2O as the diluent.
[0365] Table 3. List of reference standards used for LCMS analysis
[0366]
[0367] Qualitative analysis by liquid chromatography-mass spectrometry (LCMS)
[0368] Samples were analyzed by LCMS. Negative MS data were analyzed using Genedata software after pre-processing (RT restriction to exclude sugars, denoising, cluster identification, etc.). A total of 4,250 features were identified in all samples. 4,196 features were identified in sample A (FPX66 bound fraction), 1,127 features were identified in sample B (FPX66 unbound fraction), and 178 features were identified in sample C (74 Brix sample). Figures 4 to 6 ).
[0369] By comparison with the analyzed standards, many phenolic compounds were identified in the extract derived from sugar cane: vanillin, apigenin, orientin, vitexin, caffeic acid, chlorogenic acid, syringic acid, diosmin, angiflavone, isoorientin, diosmetin, sinapinic acid (trace), myricetin (trace), triticiflavin (trace).
[0370] Table 4 shows the polyphenol content in extracts derived from sugar cane molasses as analyzed by LCMS in μg / g dry weight.
[0371] Table 4. Polyphenol content in sample extracts derived from sugarcane molasses of the present disclosure
[0372]
[0373] Table 5 shows the properties and components of various extracts derived from sugar cane.
[0374] Table 5. Two exemplary extracts derived from sugar cane molasses of the present disclosure
[0375]
[0376] Table 6 shows a comparison of components between molasses and the sugar cane-derived extract of the present disclosure.
[0377] Table 6. Comparison between molasses and sugar cane extracts of the present disclosure
[0378]
[0379]
[0380] Table 7 shows the results in mg / kg dry weight according to Figure 1 Mineral concentrations of the sugar cane-derived extracts of the present disclosure prepared by the process of FIG. 1. The concentrations of selenium and chromium are shown in μg / kg dry weight.
[0381] Table 7. Mineral composition of representative sample extracts derived from sugar cane molasses of the present disclosure
[0382] Anions 74 Brix Sample (C) FPX66 binding sample (A) FPX66 binding sample (A) Potassium 26,000mg / kg 100-250 mg / kg 190mg / kg sodium 450mg / kg 10-50 mg / kg 30mg / kg calcium 1,090mg / kg 8,000-9,000mg / kg 8,800mg / kg magnesium 4,700mg / kg 1,500-2,500mg / kg 2,000mg / kg iron 65mg / kg 800-1000mg / kg 890mg / kg Zinc 6.6mg / kg Not detected Not detected Selenium (μg / kg) 786 μg / kg Not detected Not detected Chromium (μg / kg) 1300 μg / kg Not detected Not detected
[0383] Examples 2-12 provide illustrative and non-limiting examples of the preparation and characterization of sugar cane-derived extracts of the present disclosure.
[0384] Example 2. Sugarcane extract derived from molasses
[0385] An exemplary sugar cane extract of the present disclosure was prepared from molasses as follows.
[0386] Sugarcane molasses was diluted with deionized water and mixed thoroughly to give a final Brix of 50°. The mixture was maintained between 20-25°C and 95% food grade ethanol was added with overhead stirring to ensure that the ethanol mixture was uniformly and quickly dispersed. This step was continued until the final ethanol content reached 76% v / v. During this period, a gelatinous precipitate was formed. The precipitate was allowed to stand, the supernatant was decanted and filtered through a grade 1 Whatman GFA filter paper in a Buchner funnel under vacuum. The ethanol was then removed under reduced pressure in a Buchi rotary evaporator at 45°C. Evaporation was continued at 50-55°C under reduced pressure to give a final Brix of 70° with a bittersweet aroma. Table 8 shows the properties of an exemplary syrup obtained by this method.
[0387] Table 8. Properties of sugarcane extracts prepared from molasses
[0388]
[0389] Example 3. Fractionated sugar cane extract derived from molasses
[0390] In general, the subject fractionated sugar cane extracts can be prepared using a hydrophobic chromatography procedure. The extracts prepared using the process described in Example 2 as well as any sugar cane derived product can be used as feedstock for chromatography. The hydrophobic resin used for chromatography can be a food grade resin.
[0391] In a representative preparation, FPX66 resin (Dow, Amberlite FPX66, food grade) was pretreated according to the manufacturer's instructions: washed with deionized water, ethanol, and then washed with deionized water. The washed resin was vacuum filtered in a Buchner funnel using a grade 1 Whatman filter paper (pore size 1 μm). The resin particles were then used as is.
[0392] Deionized water was added to the cane molasses under constant stirring until the Brix reached 20°. 500 g wet weight of the pretreated resin was added to a beaker containing 1 liter of 20° Brix feed (maintained at 20-25°C) and mounted on a magnetic stirrer while gently stirring to ensure effective mixing of the resin particles with the feed. Mixing was continued for 10 minutes, at which time the mixture was filtered under vacuum and the resin was collected.
[0393] The collected resin was resuspended in deionized water (1 L) and washed. This step was repeated.
[0394] The washed resin was then suspended in 1 liter of 70% ethanol solution in deionized water, stirred for 10 minutes, and the filtrate collected by vacuum filtration. This was repeated two more times with 1 liter batches of 70% ethanol solution, collecting the filtrate each time. Finally, the three 70% ethanol filtrates were combined and the ethanol was removed by evaporation under reduced pressure. The aqueous fraction was lyophilized or spray dried to a free-flowing brown powder with a moisture content of 0.3-2.0% w / w. The properties of the ethanol fraction are shown in Table 9 below.
[0395] Table 9. Properties of extracts derived from sugar cane molasses
[0396]
[0397] Figure 5 Shown is the LC-MS spectrum of a representative extract derived from sugar cane molasses using this process flow.
[0398] Example 4. Sugarcane extract derived from dregs
[0399] Figure 2 A protocol for preparing the subject sugar cane extract is shown.
[0400] The bagasse was allowed to sit overnight in a V-bottomed tank for eight hours. The supernatant was then filtered sequentially through: (i) a 5 micron filter; (ii) a 1 micron filter; (iii) a 0.5 micron filter; and (iv) a 0.1 micron filter.
[0401] The filtered supernatant was then concentrated in a heat exchanger to remove water to obtain a liquid extract of 55° Bx.
[0402] The properties of the extracts derived from the dregs are shown in Table 10 below.
[0403] Table 10. Properties of extracts derived from dregs
[0404]
[0405] Figure 6 Shown are example LC-MS spectra of a sugarcane bagasse starting material (A) and an extract derived from bagasse of sugarcane (B) according to the process flow described above.
[0406] Example 5. Mixed sugar cane extract derived from a combination of sugar cane molasses and bagasse.
[0407] Figure 3 A protocol for preparing the subject sugar cane extract is shown. Sugar cane mill molasses is diluted with water and mixed with standing bagasse (as described above) and stirred thoroughly to obtain a mixture of 50° Bx. The combined mixture of molasses and bagasse is held at a constant temperature between 20-25°C and 95% food grade ethanol is added and stirred to ensure that the ethanol is evenly and quickly dispersed. Ethanol is added until the ethanol level is 76% v / v.
[0408] The addition of ethanol and mixing resulted in the formation of a gel-like precipitate. The precipitate in the mixture was allowed to settle and the supernatant was removed by decantation and vacuum filtration through grade 1 Whatman GFA filter paper in a Buchner funnel.
[0409] Ethanol was removed from the supernatant under vacuum in a Buchi rotary evaporator at 45° C. Water was evaporated from the supernatant under vacuum at 50-55° C. until the final syrup reached 70° Bx.
[0410] Table 11 shows the properties of the obtained mixed sugar cane extract.
[0411] Table 11. Properties of mixed sugarcane extract
[0412]
[0413] Examples 6 to 12 provide illustrative and non-limiting examples of the characterization of the anti-inflammatory and / or antioxidant activity of the sugar cane-derived extracts of the present disclosure.
[0414] Example 6. Nuclear factor κB study
[0415] illustrate
[0416] Nuclear factor kappa B (NF-κB) is a protein complex that is involved in cellular responses to stimuli such as stress and free radicals, UV irradiation, oxidized LDL, and bacterial or viral antigens. NF-κB plays a key role in regulating the immune response to infection. Inhibition of NF-κB limits the generation of pro-inflammatory gene expression and reduces inflammation levels, therefore, inhibition of NF-κB is used as an indicator of anti-inflammatory activity.
[0417] Research Methods
[0418] The test for NF-κB inhibition follows a procedure in which the test material is taken up into human cells. Pro-inflammatory cytokines are then introduced into the human cells to simulate cellular stress, which would normally induce NF-κB activation leading to inflammation. If a material that inhibits NF-κB is present in the cellular environment, the material will inhibit NF-κB activation and the extent of inhibition can be monitored by NF-κB expression. Therefore, the NF-κB expression levels of human cells treated with or without the test material under stress conditions are monitored and compared to evaluate the NF-κB inhibitory effects of the material.
[0419] First, human cells were treated with or without a representative powdered extract derived from sugar cane of the present disclosure (the extract of Example 3) to allow the extract to be naturally absorbed into the cells. The maximum percentage of inhibition of NF-κB expression induced by the powdered extract was reported as the concentration for inducing maximum inhibition of NF-κB expression. The half maximal inhibitory concentration (EC 50 ). The test results are shown in Table 12.
[0420] Table 12. Nuclear factor κB activation test results
[0421]
[0422] The response curve of this data is as follows Fig. 9 The maximum inhibition observed was 98.12%. The concentration that induced the maximum inhibition was 178 μg / mL. The half maximal response (EC 50 ) was 632.1 μg / mL. This data demonstrates that the sugar cane-derived extract of the present disclosure inhibits NF-κB, indicating anti-inflammatory activity.
[0423] Example 7. Cellular Nrf2 activation assay
[0424] illustrate
[0425] Cellular antioxidant assay (Nrf2) can be used to determine the potential of sugar cane-derived extracts of the present disclosure to stimulate Nrf2 production in human cells. Nrf2 is used as a biomarker for antioxidant and anti-inflammatory capacity (Maes, M. et al., 2012; Tan, SM and de Haan, JB, 2014).
[0426] Erythroid-derived nuclear factor 2-related factor (Nrf2) is a redox-sensitive transcription factor that binds to antioxidant response elements (AREs) to regulate the expression of antioxidant enzymes that protect against oxidative damage triggered by injury and inflammation. It has been found that activation of the Nrf2 pathway can prevent and treat a large number of chronic inflammatory diseases. Many naturally occurring phytonutrients (such as resveratrol, sulforaphane, and curcumin) have been reported to activate Nrf2, and the discovery of more phytonutrient Nrf2 activators is a focus of research. Nrf2 has been studied as a biomarker for regulating antioxidant and anti-inflammatory responses in vivo.
[0427] Research Methods
[0428] Human cells were treated with or without a representative powdered extract derived from sugar cane of the present disclosure (the extract of Example 3), and the effect of the extract on Nrf2 activation was monitored. The half maximal response (EC 50 The test results are shown in Table 13.
[0429] Table 13. Cellular Nrf2 activation test results
[0430]
[0431] The response curve of this data is as follows Fig.10 The calculated half maximal response (EC 50 ) was 632.1 μg / mL. This data demonstrates that the sugarcane-derived extract of the present disclosure activates Nrf2 and thus has antioxidant and anti-inflammatory capabilities.
[0432] Example 8. TNF-α Study
[0433] illustrate
[0434] Tumor necrosis factor-α (TNF-α) is a pro-inflammatory cytokine (a small protein that affects cell signaling) that triggers downstream cellular feedback loops to manage inflammation. TNF-α has been identified as an inflammatory trigger and precursor. Therefore, TNF-α inhibitors have the potential to act as anti-inflammatory agents.
[0435] Research Methods
[0436] First, human cells were treated with or without powdered sugar cane extract (the extract of Example 3) to allow the material to be naturally absorbed into the cells. The cells were then stressed with an inflammatory inducer that would normally stimulate TNF-α production, which would then further develop into inflammation through cell signaling. If a TNF-α inhibitor is present in the cellular environment, the material will inhibit the production of TNF-α, and the degree of inhibition can be assessed by the decreased level of TNF-α production. The levels of TNF-α production in human cells treated with or without the test material under stress conditions were monitored and compared to assess the TNF-α inhibitory effect of the test material. The maximum percentage of TNF-α expression inhibition induced by the tested sugar cane extract is reported as the concentration used to induce maximum inhibition of TNF-α expression. The test results are shown in Table 14.
[0437] Table 14. Cellular TNF-α inhibition test results
[0438]
[0439] The response curve of this data is as follows Fig.11A and Fig. 11B As shown. The maximum inhibition was observed to be 97%. The concentration that induced the maximum inhibition was 178 μg / mL. The calculated half maximal response (IC 50 ) was 36.31 μg / mL. This data demonstrates that the sugar cane-derived extract of the present disclosure inhibits TNF-α, indicating anti-inflammatory activity.
[0440] Example 9. Prostaglandin E2 (PGE2) study
[0441] illustrate
[0442] PGE2 is a primary product of arachidonic acid metabolism controlled by cyclooxygenase. It plays an important role in increasing vascular permeability, fever and tumor growth. Drugs used to inhibit PGE2 synthesis have been shown to control inflammation, pain and fever.
[0443] The inhibition of test PGE2 expression follows the program that test material is absorbed into mammalian cells.Use inflammation inducing agent to stress cell, it usually stimulates PGE2 to generate and further develops into inflammation by a series of cell signaling.But, if there is PGE2 inhibitor in cellular environment, then this material suppresses PGE2 to generate and the degree of inhibition is assessed by the declining level of PGE2 generation.Monitoring uses and does not use the PGE2 generation level in the cell processed by test material under stress conditions, and compares to assess the PGE2 inhibitory effect of test material.
[0444] Research Methods
[0445] First, mammalian cells were treated with or without powdered sugarcane extract (Example 3 extract) to allow the material to be naturally absorbed into the cells. The maximum percentage of PGE2 expression inhibition induced by the powdered extract and the concentration for inducing the maximum inhibition of PGE2 expression were reported. The half maximum effect concentration (EC 50 ). The test results are shown in Table 15.
[0446] Table 15. Cellular PGE2 inhibition test results
[0447]
[0448] The response curve of this data is as follows Fig.12 The maximum inhibition observed was 58.29%. The concentration that induced the maximum inhibition was 183.13 μg / mL. The half maximal response (IC 50 ) was 91.62 μg / mL. This data demonstrates that the sugar cane-derived extract of the present disclosure inhibits PGE2, indicating anti-inflammatory activity.
[0449] Example 10. Cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibition assay
[0450] illustrate
[0451] Cyclooxygenase-1 (COX-1) inhibitors are one of the important targets for the treatment of inflammation-related diseases. COX has two well-known isoforms: COX-1 and COX-2, which are similar in their amino acid sequence and identity. COX-2 is dominant at the site of inflammation, and COX-1 is constitutively expressed in the gastrointestinal tract. It is reported that selective COX-2 inhibitors can target inflammation and pain, reducing the risk of chronic ulcers and acute injuries (Hawkey, CJ, 2001).
[0452] Research Methods
[0453] The inhibitory capacity of representative powdered extracts derived from sugar cane (Extract of Example 3) of the present disclosure was evaluated by monitoring the effect of the extracts on the activity of specific COX enzymes using COX-1 and COX-2 inhibition assays. The assay compares the enzyme activity of the target COX in the presence and absence of the target material to determine the inhibitory potential of the material. The results are expressed as: if 50% inhibition has been achieved, the amount used to achieve 50% COX inhibition (IC 50 ) of the test material. If the IC 50The maximum percentage of COX inhibition obtained and the concentration of material used that induced the maximum inhibition are reported. The results for COX-1 and COX-2 are shown in Tables 16 and 17, respectively.
[0454] Table 16. COX-1 test results
[0455]
[0456] The inhibition curve of COX-1 data is shown in Fig.11A The maximum inhibition was 11.68%, and the effect concentration calculated at the maximum inhibition was 500.00 μg / mL.
[0457] Table 17. COX-2 test results
[0458]
[0459] The inhibition curve of COX-2 data is shown in Fig. 11B The maximum inhibition was observed to be 47.70%, and the calculated effect concentration at the maximum inhibition was 500.00 μg / mL.
[0460] This demonstrates that the sugar cane derived extract of the present disclosure is selective for COX-2 over COX- 1. Furthermore this data demonstrates that the sugar cane derived extract of the present disclosure inhibits COX-2, indicating anti-inflammatory activity.
[0461] Example 11. Cellular Antioxidant Assay (CAA)
[0462] illustrate
[0463] CAA analyzes the ability of a material to protect a fluorescent probe (as a marker) from reactive oxygen species (ROS) in the intracellular environment. In this test, peroxyl radicals were used as ROS, and human hepatocytes were used as a cell model. Quercetin was used as a standard, and the results were expressed as micromoles of quercetin equivalents (QE) per gram of sugar cane extract tested. Table 18 lists the CAA results of five extracts derived from sugar cane of the present disclosure. Extracts I, II, III, and IV were produced according to Example 2, and Extract V was produced according to Example 3.
[0464] Table 18. CAA results for five sugar cane derived extracts of the present disclosure
[0465] Sugarcane Extract Results (μmol QE / g) Extract I 48.16 Extract II 56.21 Extract III 61.37 Extract IV 67.35 Extract V 229.12
[0466] CAA is used to observe the antioxidant capacity of substances in the environment of living cells, rather than as an abstract chemical reaction. This technology aims to gain a detailed understanding of the mechanisms, bioavailability, uptake, and metabolism of antioxidant compounds in a cell culture environment, reflecting the complexity of biological systems. High CAA values indicate that antioxidant compounds have been able to enter the cells (which indicates bioavailability) without negatively affecting the cells (which would indicate toxicity). For reference, Kakadu plum (Terminalia ferdinandiana) has been found to have the highest vitamin C concentration of all fruits in the world (Brand et al. 1982). Therefore, Terminalia ferdinandiana is recognized as an extremely effective antioxidant. Terminalia ferdinandiana has been reported to have a return CAA value of 71.5±11.3 QE / gram (Tan et al. 2011). The return CAA values of the disclosed sugar cane extracts are slightly lower, within this range or significantly above this range. This shows that the sugar cane extracts of the present disclosure provide strong antioxidant protection both in vivo and in vitro environments.
[0467] Example 12. Oxygen Radical Absorbance Capacity (ORAC) Test
[0468] illustrate
[0469] The ORAC test is one of the most recognized methods for measuring antioxidant scavenging activity against oxygen free radicals, which are known to be involved in the mechanisms of aging and many common diseases (Ou et al. 2001A; Huang et al. 2002; Ou et al. 2002; Dubost et al. 2007; Zhang et al. 2009; US 7,132,296). ORAC 5.0 consists of five ORAC assays that assess the antioxidant capacity of a material against the five primary reactive oxygen species (ROS, commonly referred to as "oxygen free radicals") found in the human body: peroxyl radicals, hydroxyl radicals, peroxynitrites, superoxide anions, and singlet oxygen. The ORAC 6.0 test adds the measurement of antioxidant scavenging activity against hypochlorite. Therefore, the ORAC 5.0 / 6.0 test is a comprehensive panel for assessing antioxidant capacity.
[0470] The test is based on the principle of measuring the ability of antioxidants to protect the probe from degradation by ROS. ROS inducers are introduced into the test system. ROS inducers trigger the release of specific ROS, which degrade the probe and cause a change in its emission wavelength or intensity. However, when antioxidants are present in the system, the antioxidants absorb the ROS and protect the probe from degradation. The degree of protection of the probe indicates the antioxidant capacity of the material.
[0471] Research Methods
[0472] The ORAC 5.0 / 6.0 test was performed to evaluate the ability of four representative sugar cane extracts (Extracts A to D) of the present disclosure to protect probes (fluorescent probes or chromogens) from ROS. Trolox was used as a reference standard and the results are expressed as micromoles Trolox equivalents (TE) per gram of sugar cane extract tested. Extracts A to C were produced according to Example 2, and Extract D was produced according to Example 3.
[0473] Table 19. ORAC results for sugar cane derived extracts of the present disclosure
[0474]
[0475] The data in Table 19 demonstrate that the extracts of the present disclosure are effective in scavenging 6 well-characterized and biologically relevant oxidants. The individual ORAC values for each oxidant as well as the combined total ORAC 6 values demonstrate that the extracts of the present disclosure are potent antioxidants against a range of biologically significant oxidant species.
[0476] Examples 13 to 16 provide illustrative and non-limiting examples of the sugar cane-derived extracts, animal supplements, and animal feeds of the present disclosure improving or maintaining the health of animals (fish, chickens, cats, pigs, and horses, respectively) to facilitate improved food production and food quality.
[0477] Example 13. Fish
[0478] illustrate
[0479] Pangasa (Vietnamese Pangas, Pangasius hypophthalmus) and Tilapia (Nile Tilapia, Oreochromis niloticus) are the most and second most farmed aquatic finfish species in the world. Pangasa farming has the largest and second largest aquaculture industry in the world. For example, in Bangladesh, there is an increasing focus on promoting Pangasa farming to provide sustainable protein. Tilapia can easily adapt to tropical and subtropical regions of the world, therefore, Tilapia is considered an important fish species that can bridge the gap of increasing global demand for fish protein sources.
[0480] Shrimp (Macrobrachium rosenbergii) is one of the freshwater species of crustaceans with high potential and market demand. Currently, due to indiscriminate fishing, the catch from natural resources has been greatly reduced and the harvest has decreased. Therefore, freshwater shrimp farming is very important as a source of high-value shrimp products in the international market.
[0481] Purpose
[0482] The study evaluated the effects of the extract derived from sugar cane of the present disclosure on the growth performance including FCR of pangasius and tilapia finfish and shrimp. The study also evaluated the proximate composition, taste, flavor, odor of fish meat. In addition, the study also investigated the palatability / acceptability of the feed.
[0483] General research methods
[0484] General water quality parameters (temperature, pH, dissolved oxygen, turbidity) were monitored to ensure the right environment for the species being cultured. Data on growth performance, survival, feed conversion ratio (FCR) were collected weekly. Data on proximate composition, fish muscle taste and economic analysis were collected at the end of the study. All data were entered into MS Excel. Data management and data analysis were performed using the statistical software package SPSS (IBM).
[0485] Pangasius and Tilapia Research Methods
[0486] Pangasius (Vietnamese Pangasius) and Tilapia (Nile tilapia) were cultured in 32 special cages for four months. The dimensions of the cages were 26 feet by 12 feet. Each cage was covered with nylon ropes to prevent birds from eating the fish. The fry of Pangasius and Tilapia finfish were collected from Halda Fisheries Ltd., a supplier in Patenga, Chittagong, Bangladesh, and were checked to ensure the seed quality was good.
[0487] Four treatment groups were used in this study: T0 – control (no sugarcane extract in the feed); T1 – the amount of sugarcane extract contained in the feed was 0.2 w / w% (about 60 mg total polyphenols (TPP) per kg feed); T2 – the amount of sugarcane extract contained in the feed was 0.4 w / w% (about 120 mg TPP / kg feed); T3 – the amount of sugarcane extract contained in the feed was 0.6 w / w% (about 180 mg TPP / kg feed). Each treatment group included four cages for repeated experiments. As shown in Tables 20 and 21, the experimental design shows the distribution of pangasius and tilapia in the cages and the treatments used.
[0488] Table 20. Design of pangasius
[0489]
[0490] Table 21. Design of Tilapia
[0491]
[0492] Shrimp Research Methods
[0493] Shrimp / Golda chingri (Macrobrachium rosenbergii) were cultured in 12 tanks (3 tanks per treatment for replication). The tanks were rectangular in shape with appropriate aeration system and water exchange capacity. The experimental design shows the distribution of shrimp in the tanks and the treatments used as shown in Table 22.
[0494] Table 20. Design of shrimp
[0495]
[0496] Feed formula
[0497] Animal feeds were prepared in feed mills as per standard feed formulation specifications for fish in Bangladesh. The feed formulation used in the study including ingredients used to prepare the feed and their contents are given in Table 23 below. The feed was free of hormones and antibiotics.
[0498] Table 23. Animal feed formulations for pangasius and tilapia finfish and shrimp
[0499]
[0500] Proximate component analysis demonstrated that the formulated feed contained: moisture (14.91%); crude protein (35.41%); crude lipids (8.82%); and ash (22.4%).
[0501] Then, the extract derived from sugar cane of the present disclosure was added to the animal feed formulation in the amount of 0.2w / w%, 0.4w / w%, 0.6w / w% of the feed. The obtained feed was then fed to pangasius and tilapia finfish and shrimp. As shown in Table 24, the extract provided in the experiment had the following composition and properties.
[0502] Table 24. Composition and properties of sugarcane extracts used in fish studies
[0503]
[0504] The extract also contains the following amino acids: aspartic acid, glutamic acid, asparagine, alanine, serine, valine, and leucine.
[0505] The experimental fish were sampled regularly every other week by using a scoop net in order to check the growth performance of the fish and adjust the feeding rate. The growth performance of the fish in each sampling was measured by weight (g) and by length (cm).
[0506] result
[0507] Results for Basa fish
[0508] Sampling was completed for 16 weeks and the results are listed below in Tables 25 to 32. The abbreviations used for pangasius (and tilapia) sampling are: L* – length (cm); W* = weight (kg); LG* = growth (cm); WG* = weight gain (kg); T* = treatment group; R* = replicate.
[0509] Table 25. Pangasius sampling results from week 0 to week 2
[0510]
[0511] Table 26. Pangasius sampling results in the 3rd and 4th weeks
[0512]
[0513] Table 27. Pangasius sampling results in Week 5 and Week 6
[0514]
[0515] Table 28. Pangasius sampling results in week 7 and week 8
[0516]
[0517] Table 29. Pangasius sampling results in week 9 and week 10
[0518]
[0519] Table 30. Pangasius sampling results in weeks 11 and 12
[0520]
[0521] Table 31. Pangasius sampling results in weeks 13 and 14
[0522]
[0523] Table 32. Pangasius sampling results in weeks 15 and 16
[0524]
[0525] The initial average weight of Pangasius was 4.74 g and the initial average length was 5 cm. From the last sampling at week 16, the average weight of T0 was found to be 39.93 g, the average weight of T1 was 53.61 g, the average weight of T2 was 43.77 g, and the average weight of T3 was 45.14 g. The average length of T0 was found to be 17.1 cm, the average length of T1 was 18.63 cm, the average length of T2 was 17.8 g, and the average length of T3 was 17.98 cm. In conclusion, T1 treatment showed higher and uniform growth (in terms of weight and length) compared to other treatment groups. Figures 14 to 17 Graphs showing growth performance of Pangasius in terms of length and weight, mean weight gain and mean growth. Fig.18 and Fig.19 Shown are photos of Pangasius showing size comparisons between treatment groups.
[0526] Results for Tilapia
[0527] Sampling has been carried out for 16 weeks and the results are listed in Tables 33 to 40 below.
[0528] Table 33. Tilapia sampling results from week 0 to week 2
[0529]
[0530] Table 34. Tilapia sampling results in weeks 3 and 4
[0531]
[0532] Table 35. Tilapia sampling results in weeks 5 and 6
[0533]
[0534] Table 36. Tilapia sampling results in weeks 7 and 8
[0535]
[0536] Table 37. Tilapia sampling results in weeks 9 and 10
[0537]
[0538] Table 38. Tilapia sampling results in weeks 11 and 12
[0539]
[0540] Table 39. Tilapia sampling results in weeks 13 and 14
[0541]
[0542] Table 40. Tilapia sampling results in weeks 15 and 16
[0543]
[0544] At the time of tilapia stocking and the beginning of the study, the average weight of the fish was 2.24 g. The first sampling showed that the average weight of each treatment group T0, T1, T2 and T3 was 4.9075 g, 4.7175 g, 5.375 g and 4.665 g respectively. At the last sampling at week 16, the average weight of each treatment group T0, T1, T2 and T3 was 86.6375 g, 93.3025 g, 106.4125 g and 89.78 g respectively. This indicates that the average weight increased in the T2 (0.4%) treated diet. The average length of the fish during the stocking period was 3.21 cm. After the 16 week interval, the average length of the fish fed with the T2 (0.4%) treated diet increased. After 16 samplings, this indicates that the average weight gain increased in the T2 (0.4%) treated diet and the growth increased in the T2 (0.4%) treated diet. Figure 20 to Figure 23 Graphs showing growth performance of tilapia in terms of length and weight, mean weight gain and mean growth. Fig.24 and Fig.25 Shown are photographs of tilapia showing size comparisons between treatment groups.
[0545] Results for shrimp
[0546] The sampling results of shrimp are shown in Tables 41A to 41D (L=length (cm); LG=growth (cm); T*=treatment group; R*=replicate).
[0547] Table 41A. Growth of shrimp from sampling 1 to sampling 3
[0548]
[0549] Table 41B. Growth of shrimp from sampling 4 and sampling 5
[0550]
[0551] Table 41C. Growth of shrimp from sampling 6 to sampling 8, weight gain of shrimp from sampling 8
[0552]
[0553] Table 41D. Growth and weight gain of shrimp from sampling 9 and sampling 10
[0554]
[0555] The study showed that the growth of shrimp was the highest in the T3 treatment group. During the shrimp stocking period, the average length was 2 cm. At the 10th sampling, the average length of the T3 treatment group (0.6% dose) was 6.27 cm; the average length of the T2 treatment group (0.4% dose) was 5.22 cm; the average length of the T2 treatment group (0.2% dose) was 4.99 cm, and the average length of the T0 control group was 4.85 cm. The average weight was 2.16 g at 0.6% dose, 1.33 g at 0.4% dose, 1.07 g at 0.2% dose, and 1.24 g at the control. Figure 26 to Figure 29 Graphs showing growth performance of shrimp in terms of weight and length, average weight gain and average growth. Fig. 30A and Fig. 30B and FIG. 31A to FIG. 31C Shown are photographs of shrimp showing size comparisons between treatment groups.
[0556] Summarize
[0557] Improved growth performance
[0558] In pangasius, the best weight gain performance was found in 0.2% extract treated fish - 48.87 g compared to control fish (35.45 g). Not only 0.2% treated fish but all treated fish had higher growth performance than control.
[0559] In tilapia, the best weight gain performance - 104.1725 g was found in the fish treated with 0.4% extract compared to the control fish (84.3975 g), and the average weight gain of the 0.4% treated fish was greater than that of the control fish. Not only the 0.4% treated fish, but all the treated fish had higher growth performance than the control. The summary of the weight gain performance of pangasius and tilapia is shown in Table 42.
[0560] Table 42. Growth performance of treated pangasius and tilapia (by weight)
[0561]
[0562] Among the shrimps, the best growth performance was found in the 0.6% extract treated fish (4.27 cm) compared to the control fish (2.85 cm), and the average growth of the 0.6% extract treated fish was greater than the average growth of the control fish. Not only the 0.6% extract treated fish, but all the treated fish had higher growth performance than the control. The summary of the weight gain performance of the shrimps is shown in Table 43.
[0563] Table 43. Growth performance of treated shrimp by length
[0564]
[0565] Improved FCR
[0566] Table 44. FCR performance of treated fish
[0567]
[0568] In pangasius, the best FCR (1.49) was found in the 0.2% treated group (T1), while the FCR values of 0.4% and 0.6% treated fish (T2 and T3) were 1.83 and 1.77 respectively. All treated fish showed better FCR performance than the control fish (2.004).
[0569] In tilapia, the best FCR (1.63) was found in the 0.4% treated feed, while the FCR values of 0.2% and 0.6% treated fish were 1.854 and 1.93 respectively. All treated fish showed better FCR performance than the fish in the control group (FCR calculated as 2.00).
[0570] Among the shrimps, the best FCR (1.15) was found in the 0.6% treated shrimps, while the FCR values of 0.2% and 0.4% treated shrimps were 1.85 and 1.83 respectively. All the treated shrimps showed better FCR values than those of the control group.
[0571] smell
[0572] Immediately after completing the field study, some panelists conducted odor, flavor, and taste experiments. Panelists claimed that the treated fish tasted tastier than the control fish and that the treated fish had less odor.
[0573] Feed palatability / acceptability
[0574] The feed comprising the extract derived from sugar cane of the present disclosure was found to have little odor and attracted fish, thereby increasing feed intake. All fish were attracted to scramble for feed to consume feed of treatment groups T1, T2 and T3 compared to the control group (T0).
[0575] Increased protein content
[0576] In the pangasius, tilapia and shrimp experiments, proximate compositional analysis of each treatment group was performed and the results are shown in Table 45. All treated fish showed higher protein content than the control.
[0577] Table 45. Proximate component analysis
[0578]
[0579] Example 14. Chicken Study
[0580] Rationale
[0581] Corn is one of the most common grains in broiler diets. Corn has been reported to have rapidly digested starch (Giuberti et al., 2012). Liu and Selle, 2015, showed that feed conversion efficiency can be improved by combining slowly digested starch with rapidly digested protein.
[0582] Purpose
[0583] The objective of the study was to investigate the effect of the extract derived from sugar cane of the present disclosure (the extract of Example 4) in the diet of broiler chickens. The amount of the extract included in the diet was 0%, 0.5%, 2% and 4%, i.e., the inclusion rate was 0%, 0.5%, 2% and 4%. The effect of including the sugar cane extract of Example 4 on growth performance was examined. With respect to growth performance, the weight gain considering the feed intake of broiler chickens was examined.
[0584] Experimental design
[0585] The study envisaged corn as an example of dietary grain type, and four inclusion rates of the polyphenolic sugarcane extract of Example 4 (0%, 0.5%, 2% and 4%) gave a total of eight experimental groups. The statistical unit for growth performance was the cage, with five birds in each cage. Six replicate cages were used for each treatment group, for a total of 240 birds (8 treatments x 6 cages x 5 birds). Each of the four dietary treatments was provided from 1-35 days post-hatch as a "starter" diet (1-14 days) and a "finisher" diet (15-35 days). The starter diet and the finisher diet were formulated to commercial specifications.
[0586] statistics
[0587] The experimental unit was the combined cage mean, and differences were considered significant at P < 0.05 according to the Student t test. The experimental groups are shown in Table 45, and the dietary parameters are shown in Table 46.
[0588] Table 45. Experimental groups
[0589]
[0590] *Start (hatching day to 14 days); rearing (14 days to 42 days)
[0591] Table 46. Typical diet composition and nutritional indicators for the initial stage
[0592]
[0593] It will be appreciated that the final diet composition may vary but will generally be representative of commercial broiler starter and finisher diets.In the diet, sugar cane extract is included at the expense of corn starch.
[0594] Results and Comments
[0595] The study comprised an experimental diet consisting of corn and 4 levels (0%, 0.5%, 2% and 4%) of the sugarcane extract of Example 4, giving a total of 4 experimental groups. The analyzed data have been presented to show the effect of the extract of Example 4 in a corn / maize diet.
[0596] Growth performance
[0597] Growth performance during the study period was equal to or exceeded the recommended industry targets for Ross 308 broiler chickens (http: / / en.aviagen.com / assets / Tech_Center / Ross_Broiler / Ross-308-Broiler-PO-2014-EN.pdf). Although there were significant differences in growth performance during the initial exposure period (Days 10-17) and the subsequent exposure periods (Days 17-24) Fig. 30A and Fig. 30B ) appeared to have little effect on the mean daily gain during the period, but between days 24 and 38, a significant increase in mean daily gain was observed in group C (2% extract in the diet, Fig.31A Overall, significant weight gain was observed in Group C on Day 38 ( Fig.31B ). There was no significant change in the intake of these results, such as Fig.31C (Days 24-38) as shown.
[0598] mortality rate
[0599] Table 47. Effect of sugarcane extract (and grain type) on broiler mortality
[0600]
[0601] The extract had no adverse effect on broiler mortality throughout the growing period, even at inclusion rates of 4%. Mortality levels are in line with industry targets.
[0602] Summarize
[0603] The effects of the sugarcane extract of Example 4 at 0.5, 2 and 4% levels in a corn / maize diet were investigated because this type of diet reflects the common cereals used in intensive broiler chicken production. Feeding trials were completed with no deviation from the expected performance targets. Bird growth met or exceeded the industry targets recommended by Ross 308 Hybrids. Mortality averaged 2%, which was consistent with production targets.
[0604] The inclusion rate of sugarcane extract had little effect on weight gain during the initial exposure period (days 10-17) and subsequently from days 17-24. However, the experimental group containing 2% extract showed promising improvements in weight gain from days 24-38. This suggests that either the birds initially needed to adapt to the presence of sugarcane extract in the diet (as expected) or that the birds responded to the benefits of sugarcane extract as the gastrointestinal tract matured. The improvements in weight gain were not accompanied by significant changes in the amount of intake.
[0605] Example 15. Cat Study
[0606] Summarize
[0607] A study was conducted to test the effects of feeding an extract derived from sugar cane of the present disclosure (the extract of Example 3) on body fat and health parameters in domestic cats (Felis catus). Sixteen cats (4 years old) were fed a control diet (commercial dry food with a carrier (chicken soup)) or a control diet coated with 2% (w / w) of the extract. In a crossover design, the cats were fed the diets for a total of 30 weeks (Period 1: 1-18 weeks and Period 2: 19-30 weeks). Feeding the extract derived from sugar cane of the present disclosure had no negative effects on blood or urinary health measures. Cats fed the sugar cane extract had a lower metabolizable energy intake compared to cats fed the control diet (P=0.02). In addition, the carbohydrate digestibility of cats fed the extract was reduced (P<0.001). This may explain the reduction in body weight and body fat observed in cats fed the extract derived from sugar cane of the present disclosure.
[0608] Purpose
[0609] The purpose of the study was to determine if the sugar cane-derived extract of the present disclosure (the extract of Example 3) prevents the increase in body fat associated with consumption of a high carbohydrate diet in domestic cats.
[0610] Research Methods
[0611] animal
[0612] The protocol for this study was approved by the Massey University Animal Ethics Committee (MUEAC #15 / (revised 07 / 10)). All cats were housed at the Feline Nutrition Centre (Massey University, Palmerston North Campus, New Zealand) in accordance with the Animal Welfare (Companion Cats) Code of Welfare (2007). Prior to the study, all cats underwent a complete blood count and thyroid assessment to ensure that each cat was clinically and physiologically normal.
[0613] Two groups (n=8) of adult (4 years old) mixed-sex neutered cats (4 neutered males, 4 neutered females) were housed and fed ad libitum with a dry isocaloric diet containing the sugar cane extract of Example 3 (2%; sugar cane extract + vehicle) or without the sugar cane extract of Example 3 (vehicle only; control) for 18 weeks (balanced for sex, initial body weight (BW) and body condition score). After sampling at week 18, some cats were switched to another diet (see Fig.32 ) for 12 weeks so that the effect of sugar cane extract on reducing body fat could be determined.
[0614] diet
[0615] A commercially available adult formula dry diet was used as the basal diet. The macronutrient content of the diet is summarized in Table 48. The diet was divided into 9000 g batches. For each batch of diet, half was used to make the test diet and the remaining half was fed as a control diet. This ensured that any batch-to-batch differences in macronutrient content between the two treatment groups were minimal during the 30-week study.
[0616] Table 48. Macronutrient content of the control diet
[0617] Macronutrients content ME (metabolizable energy) protein 26% ME Fat 44% ME Carbohydrates 455mg / kJ calcium 28% phosphorus 455mg / kJ Potassium 359mg / kJ sodium 172mg / kJ chlorine - magnesium 36mg / kJ Energy supply 16.9 kJ / g Energy supply 4052kcal / g
[0618] To make the control diet, 121 g warm (25°C) chicken broth (as a vehicle, see Table 49) was added to 4535 g of the basal diet and mixed using a feed mixer. To make the 2% sugar cane extract diet, 91 g of the sugar cane-derived extract of the present disclosure was dissolved in 121 g warm (25°C) chicken broth (as a vehicle, see Table 33). This solution was added to 4535 g of the basal diet and mixed using a feed mixer. The diet was dried at room temperature (25°C) for 24 hours (until dry to the touch) and stored in a sealed container until fed to the cats.
[0619] Table 49. Macronutrient profile of carrier
[0620] Nutrients Amount per 100mL energy 4.3kJ protein 1.1g Fat (total) 0.1g Fat (saturated) 0.1g Carbohydrates (total) 1.4g Carbohydrates (sugars) 1.4g sodium 477mg
[0621] Health parameters
[0622] Prior to the start of the study (week 0), a background blood sample (2 mm L) was collected for complete blood count analysis (CBC; hematocrit, hemoglobin, red blood cell content, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelets, white blood cell count) to determine the baseline levels of animal health markers. CBC analysis was repeated at weeks 4, 9, 18, 24, and 30 of the study.
[0623] Feed intake
[0624] Animals were housed in groups according to treatment diet during the 30-week study. Food provided and rejected by the group was measured daily, and body weight (BW) of individual cats was determined weekly.
[0625] At five time points during the study (weeks 0, 4, 9, 18, 24 and 30), daily feces and urine were collected to determine the daily feed intake of each single animal within a week. The apparent digestibility of macronutrients (carbohydrates, proteins, fats and energy) in each diet was determined using a standard digestibility protocol. In brief, individual food intake and rejection were recorded daily, and total urine and fecal excretion were collected over a period of 5 days. Fecal samples were frozen (-20°C), freeze-dried and ground for analysis.
[0626] The diets were analyzed for percent moisture using a 105°C convection oven (AOAC 930.15, 925.10), percent ash using a 550°C furnace (AOAC 942.05), percent protein using the leco gross combustion method (AOAC 968.06), percent fat using the acid hydrolysis / Maurice extraction method (AOAC 954.02), gross energy (kJ / g) using bomb calorimetry, percent crude fiber using the gravimetric method (AOAC 978.10 Animal Feeds), and percent carbohydrates by differential analysis.
[0627] Metabolite analysis
[0628] Urine samples (250 μL) were collected from the tray within 1 hour of voiding, snap frozen in liquid nitrogen, and stored at -85°C until analysis. Urine samples (4 μL urine in 200 μL 0.1% formic acid) were analyzed by reverse phase UHPLC-MS method, and mass spectrometry ions indicating changes in metabolic processes were selected and monitored. These candidate ions were then further characterized / identified in a limited number of samples by standard LC with targeted MS-MSn. The selection of candidates was also based on the elimination of adduct ions, isotopes, weak intensity peaks, or more difficult candidates (multiple charged and / or high mass candidates).
[0629] Body composition
[0630] Deuterium oxide (D2O)
[0631] Body composition was determined using deuterium oxide (D2O) injected into the jugular vein of the animals at weeks 0, 4, 9, 18, 24, and 30 (Backus et al., 2000). Briefly, cats were injected with D2O at a dose of 0.4 g / kg BW (Backus et al., 2000). Food and water were withheld for 24 hours prior to administration. A baseline blood sample (day 0) was collected by jugular vein puncture prior to intravenous injection with labeled water. Blood samples (2 mL) were collected 4 hours after injection, plasma was separated and frozen at -20°C until analysis. 2 H enrichment was determined by transferring hydrogen from water to acetylene and subsequently analyzing acetylene isotopes by IRMS (Van Kreel et al., 1996). The method was adapted and improved by converting acetylene eluted from a gas chromatograph (GC) into hydrogen and analyzing the resulting hydrogen. Briefly, 350 mg of granular calcium carbide (Sigma) was transferred to a 12 mL sample bottle (Labco, UK), sealed with a bottle cap and septum, and then evacuated. Plasma (20 μL) was injected onto the calcium carbide bed through the septum and allowed to react at room temperature for a minimum of 30 minutes before analysis on a GC-TC-IRMS. Headspace acetylene in plasma was analyzed using a Thermo Finnigan Delta Vplus continuous flow isotope ratio mass spectrometer (Thermo-Finnigan, Bremen, Germany) online with a Thermo Trace GC via a Thermo Conflow III combustion interface (high temperature pyrolysis furnace at 1450°C). 2H enrichment determination. Acetylene eluted from the GC column is pyrolyzed into H2. After drying with a nafion membrane gas flow, the gas is introduced into the IRMS ion source. A capillary column (Agilent Poraplot Q, 30m×0.32mm ID) with helium as carrier gas (1.5mL / min) is used to separate acetylene from air components. 15μL is injected in a partition mode (1:20 partition ratio) by an automatic sampler (CTC A200S; CTCanalytics, Zwingen, Switzerland) equipped with a 100μL headspace syringe. The column head pressure is 150kPa and the injection port temperature is 110°C. During the run, the GC column box temperature is maintained isothermally at 110°C. Data processing is performed by the software ISODAT provided by the supplier. For IRMS calibration, a mixture of D2O and unlabeled H2O (0 to 5mg D2O per mL H2O) is prepared and analyzed in a similar manner to plasma samples.
[0632] Dual-energy X-ray absorptiometry
[0633] Body composition was also determined using dual-energy X-ray absorptiometry (DEXA; Speakman et al., 2001) at weeks 0, 4, 9, 18, 24, and 30. Cats were sedated with medetomidine (10 μg / kg BW; 1 mg / mL) by a qualified veterinarian 4 hours after blood sampling for the D2O study. Cats were placed on their sides and monitored on a Discovery A (S / N 82414) DEXA ( Scans were performed on a 40-well plate at 145-well plate (Denver, CO, USA) using the "whole body" and "baby whole body" settings. Cats were given butorphanol (100 μg / kg BW; 10 mg / mL) immediately after scanning to reverse the effects of sedation and were monitored for 2 hours. Once the cats were alert, they were provided with food and water according to their dietary allocation.
[0634] calculate
[0635] Digestibility coefficients for dry matter, energy, fat, carbohydrates, and protein were determined using the following method: digestibility % = [(amount in diet – amount in feces) / amount in diet] × 100 (Wichert et al., 2009). Metabolizable energy intake (MEI) was calculated by correcting the total energy content of the diet (determined by bomb calorimetry) for energy digestibility and crude protein content. Body fat was calculated using the isotope washout method (Backus et al., 2001).
[0636] statistics
[0637] All parameters were analyzed using a linear mixed model with REML variance component analysis (GenStat v12). Period was defined as the diet consumed during period 1 (weeks 4, 9, and 18) or period 2 (weeks 24 and 30). The model included period treatment*sex as fixed parameters and cat*period as random effects. Week 0 was used as a covariate for all analyses. Data are reported as mean and standard deviation (SED). Probabilities below 0.05 were considered significant, and values between 0.05 and 0.10 were trends. Two cats were omitted from the analysis at week 30 due to abnormally low intake (less than 40% of the previous measurement).
[0638] Results and discussion
[0639] Effects of sugarcane extract on hematological and urinary health parameters
[0640] Blood health parameters of the cats were assessed using a CBC at weeks 0, 4, 9, 18, 24, and 30 of the study. The CBC test measures the following: the number of red blood cells (RBC), the number of white blood cells (WBC), the total amount of hemoglobin in the blood, the portion of the blood that is made up of red blood cells (hematocrit). The CBC test also provides information about the following measurements: mean corpuscular volume (MCV), the amount of hemoglobin per red blood cell (MCH), the amount of hemoglobin per red blood cell relative to the size of the cell (hemoglobin concentration) (MCHC). This test can reveal problems with RBC production and destruction, or help diagnose malnutrition, kidney disease, dehydration, infection, allergies, and clotting problems. The MCV, MCH, and MCHC values reflect the size and hemoglobin concentration of individual cells and can be used to diagnose different types of anemia.
[0641] All health parameters were within normal range at all points during the study period. Fig.33 and Fig.34 As shown, feeding the compound had no negative impact on health parameters. Although cats fed the sugar cane extract had increased MCH (P=0.03) and MCHC (P=0.05), these values were still within the normal range (MCH and MCHC were 13-18 pg and 290-360 g / L, respectively). Therefore, feeding the sugar cane-derived extract of the present disclosure does not have a negative impact on the health of cats.
[0642] Effects of feeding sugarcane extract on urinary markers of health in cats Fig.35 A and Fig.35Figure B. The extract increased the urine pH of cats (P = 0.002). Cats need acidic urine to maintain urinary tract health. Experts agree that the healthy range is 6.0 to 6.5, although the upper range may vary in some cases. pH values above 6.5 can lead to the growth of struvite stones (magnesium ammonium phosphate crystals). pH values below 6.0 can lead to the formation of calcium oxalate crystals. In the current study, urine pH values were within the normal range for both diets.
[0643] Feeding the sugar cane extract had no effect on urine specific gravity. Specific gravity is an important measure of how concentrated the urine is in the cat's kidneys, and therefore, how well the kidneys are functioning as filters. The normal range for specific gravity is between 1.015 and 1.060, but only concentrations above about 1.030 are considered strong evidence of normal kidney function. Therefore, it appears that feeding the sugar cane-derived extract of the present disclosure does not negatively affect the urinary health of domestic cats.
[0644] Effects of Sugarcane Extract on Food Intake and Digestibility
[0645] The macronutrient profiles of the control and test diets were determined by proximate analysis and are shown in Table 50. The following abbreviations are used: dry matter (DM); gross energy (GE); crude fiber (CF).
[0646] Table 50. Macronutrient Content of Control Diet and Sugarcane Extract Diet Fed to Domestic Cat Subjects
[0647] diet DM(%) Ash content (%) protein GE Fat(%) CF Comparison 91.9 4.9 31.5 21.4 21.0 1.3 sugar cane 91.1 4.8 31.0 21.2 20.4 1.2
[0648] Total daily metabolizable energy intake (kcal / day) was reduced in cats fed the sugar cane extract (P<0.001) (Table 51). When metabolizable energy (ME) intake was expressed as a function of body weight (BW), which is how cats' energy requirements are usually reported, cats fed the sugar cane-derived extract of the present disclosure had a reduced metabolizable energy intake (P value = 0.02).
[0649] Table 51. Effect of feeding the sugar cane-derived extract of the present disclosure on daily dry matter and energy intake of domestic cats
[0650] Comparison Extracts SED P-value ME intake (kcal / day) 308.1 238.4 18.03 <0.001 ME intake (kcal / kg BW / day) 68.97 59.41 3.96 0.02
[0651] Digestibility of macronutrients Fig.36 The sugarcane extract had no effect on the digestibility of protein (P = 0.55) and fat (P = 0.48). Cats fed the extract showed a trend toward decreased digestibility of energy (P = 0.06), as well as decreased digestibility of dry matter (P = 0.01) and carbohydrates (P < 0.001).
[0652] Effects of Sugarcane on Body Weight and Body Composition
[0653] Cats fed the sugar cane-derived extract of the present disclosure (Extract of Example 3) maintained their body weight, while those fed the control diet gained weight ( Fig.37B ). Therefore, the cats fed the extract of Example 3 had a reduced body weight relative to the control. In this regard, Fig.38 The results of a crossover of cats fed a control diet to a sugar cane extract diet based on the extract of Example 3 are shown. It was observed that cats that started on a control diet and then switched to a sugar cane extract diet lost all the weight they had gained in the first 18 weeks ( Fig.38 (line marked with "CX" in the middle).
[0654] Body composition was assessed using DEXA and deuterated water to assess lean body mass and body fat levels. Body fat levels of cats fed the extract of Example 3 relative to fat % and fat mass ( Fig.39A and 39B ) and lean body mass ( Fig.37A ). In addition, although little difference in energy intake was observed between the sugarcane extract diet and the control diet ( Fig.40 ), but the body fat level was significantly reduced, such as Fig.41 This showed that cats fed the sugar cane extract diet had 29% less fat than cats fed the control diet.
[0655] in conclusion
[0656] Cats fed the sugar cane-derived extract of the present disclosure had reduced body fat levels with respect to both fat % and fat mass as well as lean body mass. Cats fed the sugar cane-derived extract of the present disclosure had reduced body weight ( Fig.39B ). The sugar cane-derived extract of the present disclosure had no negative effects on blood or urine markers of feline health. Feeding the extract reduced energy and carbohydrate digestibility. Total intake and metabolizable energy intake were also reduced in cats fed the extract, but were within the normal range for adult cats, suggesting that the extract acts to increase satiety in domestic cats.
[0657] Example 16. Horse Research
[0658] Purpose
[0659] The sugar cane-derived extracts of the present disclosure were evaluated in horses. The study design was multifaceted and involved evaluation of the following effects: nutrient digestibility and hindgut digestive function; stimulation or maintenance of appetite, weight gain or weight change; muscle condition, such as muscle structure, shape, and overall appearance of equine subjects.
[0660] Research Methods
[0661] The study has three parts:
[0662] In the stabilization study, the study group included a group of horses that were not administered any anti-ulcer drugs. The horses were fed daily with the extract derived from sugar cane of the present disclosure mixed in their feed. Photos of the horses were taken before and after treatment (this section is hereinafter referred to as the stabilization study).
[0663] After feeding horses with the sugarcane-derived extract of the present disclosure for 8 to 12 weeks, a number of horse trainers, horsemen / equestrians were asked to answer a questionnaire. The questionnaire covered the following issues: appetite; weight change; nutrient digestion and hindgut function (this section is hereinafter referred to as the questionnaire section).
[0664] Regarding the effects of the sugar cane-derived extract of the present disclosure on the health of horses, a further case study was conducted through testimonials from horse owners (this section is hereinafter referred to as the testimonial section).
[0665] The sugar cane extract used in the experiments was produced according to Example 5 and is listed in Table 52 below.
[0666] Table 52. Properties of Sugarcane Extracts Used in Horse Trials
[0667]
[0668] result
[0669] Stability studies
[0670] The results of the stability study are shown in Table 53 below. Photos of the appearance of horses A to E before and after are shown in Table 53. FIG. 42A to FIG. 46B shown.
[0671] Table 53. Weight measurements before and after
[0672]
[0673]
[0674] exist FIG. 42A to FIG. 46B The photographs shown indicate a beneficial improvement in the horse's appearance.
[0675] Questionnaire
[0676] The responses received regarding appetite; weight gain / loss; nutrient digestion and hindgut function are shown below. The responses and comments are listed in Tables 54A and 54B below.
[0677] Table 54A. Questionnaire responses
[0678]
[0679] Table 54B. Questionnaire responses
[0680]
[0681] The comments indicated that the sugar cane derived extract of the present disclosure had a beneficial and significant effect on appetite. Almost all respondents noted that the horses' appetite was stimulated or maintained. In addition, a healthy body weight was maintained. Although one response indicated that normal weight fluctuations were observed, many responses indicated that significant weight gain was observed. Importantly, there was a positive effect on digestion / hindgut function. Most respondents noted that no undigested grain was observed in the feces / excrement.
[0682] Testimonials
[0683] When treated with the sugar cane-derived extract of the present disclosure, the equine subject showed increased topline due to improved muscle condition. The horse, described as a picky eater, was found to eat hard feed every night despite a history of gastric ulcers. The horse was also observed to show more energy.
[0684] Summarize
[0685] The sugar-derived extracts of the present disclosure are able to improve or maintain the health of horses. Appetite is stimulated or maintained. Interestingly, this effect on appetite is maintained in the presence of gastric ulcer syndrome ("GUS"). This is particularly relevant because one of the main clinical effects of GUS is a decrease in appetite. This then has a "rolling" effect because horse trainers often modify and reduce training regimes when horses stop eating properly. In this study, the treated horses were able to maintain their appetite despite the presence of GUS, so there was no need to modify feeding practices.
[0686] Example 17. Supplements containing fiber
[0687] The sugar cane-derived extract of the present disclosure was developed into a supplement containing fiber. The fiber was ground chia seeds coated on the extract in an amount of 2% or 5% of the total weight of the additive.
[0688] Supplements containing chia fiber are listed in Table 55 below.
[0689] Table 55. Supplements containing chia fiber
[0690]
[0691] Example 18. Chicken Study
[0692] Purpose
[0693] The sugarcane-derived extracts of the present disclosure were evaluated in Ross 308 broiler chickens. The study design was multifaceted and involved the evaluation of the following effects under normal growth conditions (“thermoneutral”, TN) and under “heat stress” (HS) conditions:
[0694] Growth performance (weight gain, feed consumption and feed conversion rate)
[0695] Meat quality (Warren-Brown shear force, color, drip loss, moisture content, lipid peroxidation, myofibrillar fragmentation index)
[0696] Research Methods
[0697] Broiler chicks were received from the hatchery as one-day-old chicks. Half of the chicks were grown under TN conditions and the other half under HS conditions ( Fig.47 Broiler chickens were fed an industry-based standard diet for starter, grower and finisher supplemented with 0, 2, 4, 6 and 10 g / kg of the extract derived from sugar cane of the present disclosure and 1 g / kg betaine. The chickens were grown to a maximum of 42 days and then electroshocked and euthanized to determine product quality.
[0698] Broiler chickens were fed a wheat-based diet matching the standard "starter" (0-14 days), "grower" (15-28 days) and "finisher" (29-finish) formulations commonly used in the Australian poultry industry.
[0699] Respiratory rate and rectal temperature were measured weekly from day 14 until the end of the experiment. On the penultimate day of the experiment, blood samples were collected and blood gas analysis was performed.
[0700] Meat quality was determined by Walter-Brown shear force (WBSF, an instrumental measure of tenderness), myofibrillar fragmentation index (MFI, an indirect measure of calpain-mediated degradation of skeletal muscle fibers during meat tenderization), color, lipid peroxidation, thiobarbituric acid reactive substances (TBARS), and water holding capacity (dry weight, drip, and cooking loss %).
[0701] result
[0702] Growth parameters
[0703] At day 35, the final body weight of broilers supplemented with the extract derived from sugar cane of the present disclosure increased linearly in both TN and HS groups (P=0.002, Fig.48 ), with the most effective inclusion level of 10 g / kg (P=0.038). Broilers grown under HS conditions tended to be lighter (P=0.069), but no interaction between sugarcane-derived extract and HS was observed (Table 56).
[0704] No effect of sugarcane-derived extract on feed intake was observed. However, since sugarcane-derived extract increased body weight, this resulted in a significant improvement in feed conversion ratio (FCR, P = 0.057, Fig.49 ) showed an improving (decreasing) trend.
[0705] Meat quality
[0706] For example, the Walden-Brown shear force (WBSF, Fig.50 ), with the inclusion rate of 10 g / kg providing the greatest benefit. Heat stress increased WBSF, indicating tougher meat (21.0 and 24.1 for TN and HS, P<0.001), but no interaction with the sugarcane derived extract was observed (P=0.26, Table 57). Postmortem proteolytic degradation of myofibrils leads to the production of myofibril fragments and is an important precursor to the meat tenderization process. Myofibrillar fragmentation index (MFI) was not affected by the sugarcane derived extract of the present disclosure (P=0.17), but was lower in HS broilers, indicating a reduction in postmortem proteolytic activity (P=0.007, Table 57).
[0707] Lipid oxidation was quantified by TBARS analysis ( FIG. 51( a ) (TN group) and FIG. 51( b ) (HS group)) and was significantly higher at 72 h than at 24 h in the control meat samples. In contrast, in the muscle samples supplemented with the sugar cane-derived extract, TBARS levels did not increase between 24 and 72 h. This result suggests that the presently disclosed extract derived from sugar cane improves lipid stability, especially at 72 h, which is the time when consumers would normally purchase chicken.
[0708] Summarize
[0709] 0 (control), 2, 4, 6 and 10 g / kg of sugarcane derived extract of the present disclosure was supplemented to Ross 308 broiler chickens from day 1 to day 35. The main findings were that the sugarcane derived extract increased final body weight and tended to improve feed conversion. In addition, it improved product quality making breast meat more tender. Furthermore, the meat of broiler chickens supplemented with the sugarcane derived extract of the present disclosure showed improved lipid stability, which is an important determinant of shelf life. The most effective dose of sugarcane derived extract was 10 g / kg.
[0710] Table 56. Effects of heat stress and sugarcane derived extracts on growth performance parameters
[0711]
[0712] Table 57. Effects of heat stress and sugarcane derived extracts on meat quality parameters
[0713]
[0714] References
[0715] The Merck Veterinary Manual,11 th Edition, 2016, Merck (TheMerckVeterinary Manual).
[0716] CRC Handbook of Food Drug and Cosmetic Excipients,1 st Ed., 1992, SCSmolinske, CRC Press (CRC Handbook of Food Drug and Cosmetic Excipients, 1992).
[0717] Maes, Michael, et al. "New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3inhibitors." Inflammopharmacology 20.3 (2012): 127-150 (Maes, M. et al. (2012)).
[0718] Tan, Sih Min, and Judy B. de Haan. "Combating oxidative stress indiabeticcomplications with Nrf2 activators: how much is too much?." RedoxReport 19.3(2014):107-117(Tan, SM and de Haan, JB, 2014).
[0719] Hawkey,C.J."COX-1and COX-2inhibitors."Best Practice&ResearchClinicalGastroenterology 15.5(2001):801-820(Hawkey,C.J,2001).
[0720] Boxin Ou,Maureen Hampsch-Woodill,and Ronald L.Prior."Developmentandvalidation of an improved oxygen radical absorbance capacity assayusingfluorescein as the fluorescent probe."Journal of Agricultural andFoodchemistry 49.10(2001):4619-4626(Ou et al.2001).
[0721] Dejian Huang,Boxin Ou,Maureen Hampsch-Woodill,Judith A.Flanagan,andElizabeth K.Deemer"Development and validation of oxygen radicalabsorbancecapacity assay for lipophilic antioxidants using randomlymethylatedβ-cyclodextrin as the solubility enhancer."Journal of Agriculturaland FoodChemistry 50.7(2002):1815-1821(Huang et al.2002).
[0722] Boxin Ou,Maureen Hampsch-Woodill,Judith Flanagan,Elizabeth K.Deemer,Ronald L.Prior,and Dejian Huang"Novel fluorometric assay for hydroxylradicalprevention capacity using fluorescein as the probe”Journal ofAgriculturaland Food Chemistry 50.10(2002):2772-2777(Ou et al.2002).
[0723] N.Joy Dubost,Boxin Ou,Robert B.Beelman"Quantification ofpolyphenolsand ergothioneine in cultivated mushrooms and correlation tototalantioxidant capacity."Food Chemistry 105.2(2007):727-735(Dubost etal.2007).
[0724] Liliang Zhang,Dejian Huang,Miwako Kondon,Ellen Fan,Hongping Ji,YanKouand Boxin Ou"Novel high-throughput assay for antioxidant capacityagainstsuperoxide anion."Journal of Agricultural and Food chemistry 57.7(2009):2661-2667(Zhang et al.2009).
[0725] Boxin Ou,Dejian Huang,and Maureen H.Woodill(Inventors)"Methodforassaying the antioxidant capacity of a sample"U.S.Patent No.7,132,296.(US7,132,296).
[0726] Giuberti G,Gallo A,Cerioli C,Masoero F(2012)Animal Feed ScienceandTechnology 174,163-173(Giuberti et al.,2012).
[0727] Liu SY,Selle PH(2015)Worlds Poultry Science Journal 71,297-310(LiuandSelle,2015).
[0728] Backus RC,Havel PJ,Gingerich RL&Rogers QR(2000)Relationshipbetweenserum leptin immunoreactivity and body fat mass as estimated by use ofanovel gas-phase Fourier transform infrared spectroscopy deuteriumdilutionmethod in cats.American Journal of Veterinary Research 61,796-801(Backus etal.,2000).
[0729] Van Kreel BK,Van der Vegt F,Meers M,Wagenrnakers T,Westerterp K&Coward A(1996)(Van Kreel et al.1996).
[0730] Speakman JR,Booles D&Butterwick R(2001)Validation of dual energy X-ray absorptiometry(Speakman et al.,2001).
[0731] Wichert B,Schade L,Gebert S,Bucher B,Zottmaier B,Wenk C&Wanner M(2009)Energy and protein needs of cats for maintenance,gestationandlactation.Journal of Feline Medicine&Surgery 11,808-815(Wichert et al.,2009).
[0732] Backus RC,Ginzinger DG,Ashbourne Excoffon KJ,Clee SM,Hayden MR,EckelRH,Hickman,MA&Rogers QR(2001)Maternal expression of functionallipoproteinlipase and effects on body fat mass and body condition scores ofmature catswith lipoprotein lipase deficiency.American Journal of VeterinaryResearch62,264-269(Backus et al.,2001).
[0733] Brand,J.,Cherikoff,V.Lee,A.,&Truswell,A.S.(1982),An outstandingfoodsource of vitamin C.The Lancet,320(8303),873(Brand et al.1982).
[0734] Tan,A.C.,Konczak,I.,Ramzan,I.,Zabaras,D.,&Sze,D.M.Y.(2011),Potentialan tioxidant,antiinflammatory,and proapoptotic anticancer activitiesof Kakaduplum and Illawarra plum polyphenolic fractions.Nutrition and cancer,63(7),1074-1084(Tan et al.2011)。
Claims
1. A non-human animal formula supplement comprising an extract derived from sugar cane, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
2. A non-human animal feed comprising the supplement according to claim 1.
3. The feed of claim 2, wherein the supplement is present in the feed in an amount of up to about 2 wt%.
4. Use of an extract derived from sugar cane, comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols in the preparation of a non-human animal formula supplement for: (i) improving or maintaining gastrointestinal health in non-human animal subjects; or (ii) improving growth performance in a non-human animal subject; or (iii) reducing body fat content in a non-human animal subject; or (iv) for improving nutrient digestibility in non-human animal subjects; or (v) reduce the feed conversion ratio (FCR) of a non-human animal subject; or (vi) improving the quality of meat from non-human animal subjects; or (vii) improving or maintaining muscle condition in a non-human animal subject; or (viii) stimulating or maintaining appetite in a non-human animal subject.
5. Use of an extract derived from sugar cane in the manufacture of a medicament for preventing and / or treating anemia in a non-human animal subject, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
6. Use of an extract derived from sugar cane in the manufacture of a non-human animal formula supplement, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols.
7. A non-human animal formula supplement comprising an extract derived from sugar cane, the extract comprising about 10 catechin equivalent (CE) g / L to about 50 CE g / L of polyphenols or about 100 CE mg / g to about 500 CE mg / g of polyphenols, wherein the extract comprises iron bound to the polyphenols.
8. A non-human animal feed comprising the supplement according to claim 7.
9. The feed of claim 8, wherein the supplement is present in the feed in an amount of up to about 2 wt%.
10. The supplement or feed or method or use of claim 9, wherein the extract comprises about 20 CE g / L to about 30 CE g / L of polyphenols or about 200 CE mg / g to about 300 CE mg / g of polyphenols.
